<SEC-DOCUMENT>0001628908-23-000061.txt : 20230503
<SEC-HEADER>0001628908-23-000061.hdr.sgml : 20230503
<ACCEPTANCE-DATETIME>20230503161527
ACCESSION NUMBER:		0001628908-23-000061
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20230503
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230503
DATE AS OF CHANGE:		20230503

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Evolent Health, Inc.
		CENTRAL INDEX KEY:			0001628908
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MANAGEMENT SERVICES [8741]
		IRS NUMBER:				320454912
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37415
		FILM NUMBER:		23884152

	BUSINESS ADDRESS:	
		STREET 1:		800 NORTH GLEBE RD, SUITE 500
		CITY:			ARLINGTON
		STATE:			VA
		ZIP:			22203
		BUSINESS PHONE:		571-389-6000

	MAIL ADDRESS:	
		STREET 1:		800 NORTH GLEBE RD, SUITE 500
		CITY:			ARLINGTON
		STATE:			VA
		ZIP:			22203
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>evh-20230503.htm
<DESCRIPTION>05.03.2023 8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:48ec9819-1b32-4ab5-9021-0a110d0fc8c7,g:2317c2b5-139d-451b-b061-2d090df0b68c,d:444b112ca57b42059b60a9a9f4ff8a04--><html xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>evh-20230503</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="id598b4ef6927435d9f551b05ce16b3bb_D20230503-20230503" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NGIxMTJjYTU3YjQyMDU5YjYwYTlhOWY0ZmY4YTA0L3NlYzo0NDRiMTEyY2E1N2I0MjA1OWI2MGE5YTlmNGZmOGEwNF80L2ZyYWc6YzE5MjBlN2FhMmYzNDkyYTgxMWJhYjY5MGY1OGMzMWQvdGFibGU6MzA0MDQ2ZWFhODNkNGRmN2JlZTRiMTRmZDkzODhiMGMvdGFibGVyYW5nZTozMDQwNDZlYWE4M2Q0ZGY3YmVlNGIxNGZkOTM4OGIwY18zLTEtMS0xLTEwMTQxNw_0226155c-8bd0-400b-bad2-11aea14923d0">0001628908</ix:nonNumeric><ix:nonNumeric contextRef="id598b4ef6927435d9f551b05ce16b3bb_D20230503-20230503" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NGIxMTJjYTU3YjQyMDU5YjYwYTlhOWY0ZmY4YTA0L3NlYzo0NDRiMTEyY2E1N2I0MjA1OWI2MGE5YTlmNGZmOGEwNF80L2ZyYWc6YzE5MjBlN2FhMmYzNDkyYTgxMWJhYjY5MGY1OGMzMWQvdGFibGU6MzA0MDQ2ZWFhODNkNGRmN2JlZTRiMTRmZDkzODhiMGMvdGFibGVyYW5nZTozMDQwNDZlYWE4M2Q0ZGY3YmVlNGIxNGZkOTM4OGIwY182LTEtMS0xLTEwMTQxNw_191a14b3-1ef7-4703-9820-a3c078eac4a3">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="evh-20230503.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="id598b4ef6927435d9f551b05ce16b3bb_D20230503-20230503"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-03</xbrli:startDate><xbrli:endDate>2023-05-03</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i444b112ca57b42059b60a9a9f4ff8a04_1"></div><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:100%">UNITED STATES</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:100%">SECURITIES AND EXCHANGE COMMISSION</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">WASHINGTON, D.C. 20549</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">_________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="id598b4ef6927435d9f551b05ce16b3bb_D20230503-20230503" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NGIxMTJjYTU3YjQyMDU5YjYwYTlhOWY0ZmY4YTA0L3NlYzo0NDRiMTEyY2E1N2I0MjA1OWI2MGE5YTlmNGZmOGEwNF8xL2ZyYWc6ZTkxNDZhZGU1OWMwNDNmZThhYjIzZTEyNzQ4YjI2MjYvdGV4dHJlZ2lvbjplOTE0NmFkZTU5YzA0M2ZlOGFiMjNlMTI3NDhiMjYyNl8xNjYx_30efb3f0-297e-47bc-b24c-1bb725c6766b">8-K</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">_________________________</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Pursuant to Section 13 or 15(d) of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Securities Exchange Act of 1934</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline"><ix:nonNumeric contextRef="id598b4ef6927435d9f551b05ce16b3bb_D20230503-20230503" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NGIxMTJjYTU3YjQyMDU5YjYwYTlhOWY0ZmY4YTA0L3NlYzo0NDRiMTEyY2E1N2I0MjA1OWI2MGE5YTlmNGZmOGEwNF8xL2ZyYWc6ZTkxNDZhZGU1OWMwNDNmZThhYjIzZTEyNzQ4YjI2MjYvdGV4dHJlZ2lvbjplOTE0NmFkZTU5YzA0M2ZlOGFiMjNlMTI3NDhiMjYyNl8xNTc_14be21b8-ae48-4e91-afc5-15d28abed17f">May 3, 2023</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Date of Report (Date of earliest event reported)  &#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="id598b4ef6927435d9f551b05ce16b3bb_D20230503-20230503" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NGIxMTJjYTU3YjQyMDU5YjYwYTlhOWY0ZmY4YTA0L3NlYzo0NDRiMTEyY2E1N2I0MjA1OWI2MGE5YTlmNGZmOGEwNF8xL2ZyYWc6ZTkxNDZhZGU1OWMwNDNmZThhYjIzZTEyNzQ4YjI2MjYvdGV4dHJlZ2lvbjplOTE0NmFkZTU5YzA0M2ZlOGFiMjNlMTI3NDhiMjYyNl8xNjYy_2f9d3425-9ee2-4632-9bec-c25d3080ef07">Evolent Health, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">_________________________</span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:384.75pt"><tr><td style="width:1.0pt"></td><td style="width:109.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:6.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:7.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:7.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:37.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:7.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:103.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="id598b4ef6927435d9f551b05ce16b3bb_D20230503-20230503" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NGIxMTJjYTU3YjQyMDU5YjYwYTlhOWY0ZmY4YTA0L3NlYzo0NDRiMTEyY2E1N2I0MjA1OWI2MGE5YTlmNGZmOGEwNF8xL2ZyYWc6ZTkxNDZhZGU1OWMwNDNmZThhYjIzZTEyNzQ4YjI2MjYvdGFibGU6NmNiNGY4NzAwOGE0NDI1MjlhNGI0Mjg5ODcwY2YxZmEvdGFibGVyYW5nZTo2Y2I0Zjg3MDA4YTQ0MjUyOWE0YjQyODk4NzBjZjFmYV8wLTAtMS0xLTEwMTQxNw_21e1c84c-2cee-445a-9f12-b91e9fe249a8">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="id598b4ef6927435d9f551b05ce16b3bb_D20230503-20230503" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NGIxMTJjYTU3YjQyMDU5YjYwYTlhOWY0ZmY4YTA0L3NlYzo0NDRiMTEyY2E1N2I0MjA1OWI2MGE5YTlmNGZmOGEwNF8xL2ZyYWc6ZTkxNDZhZGU1OWMwNDNmZThhYjIzZTEyNzQ4YjI2MjYvdGFibGU6NmNiNGY4NzAwOGE0NDI1MjlhNGI0Mjg5ODcwY2YxZmEvdGFibGVyYW5nZTo2Y2I0Zjg3MDA4YTQ0MjUyOWE0YjQyODk4NzBjZjFmYV8wLTItMS0xLTEwMTQxNw_b5b3d7f6-861c-45e4-bb87-0061b27f95a6">001-37415</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="id598b4ef6927435d9f551b05ce16b3bb_D20230503-20230503" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NGIxMTJjYTU3YjQyMDU5YjYwYTlhOWY0ZmY4YTA0L3NlYzo0NDRiMTEyY2E1N2I0MjA1OWI2MGE5YTlmNGZmOGEwNF8xL2ZyYWc6ZTkxNDZhZGU1OWMwNDNmZThhYjIzZTEyNzQ4YjI2MjYvdGFibGU6NmNiNGY4NzAwOGE0NDI1MjlhNGI0Mjg5ODcwY2YxZmEvdGFibGVyYW5nZTo2Y2I0Zjg3MDA4YTQ0MjUyOWE0YjQyODk4NzBjZjFmYV8wLTgtMS0xLTEwMTQxNw_138e9b8a-b677-4ce3-9e29-44940f1a1fb5">32-0454912</ix:nonNumeric></span></td></tr><tr style="height:20pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Commission File Number:&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="id598b4ef6927435d9f551b05ce16b3bb_D20230503-20230503" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NGIxMTJjYTU3YjQyMDU5YjYwYTlhOWY0ZmY4YTA0L3NlYzo0NDRiMTEyY2E1N2I0MjA1OWI2MGE5YTlmNGZmOGEwNF8xL2ZyYWc6ZTkxNDZhZGU1OWMwNDNmZThhYjIzZTEyNzQ4YjI2MjYvdGFibGU6NmNiNGY4NzAwOGE0NDI1MjlhNGI0Mjg5ODcwY2YxZmEvdGFibGVyYW5nZTo2Y2I0Zjg3MDA4YTQ0MjUyOWE0YjQyODk4NzBjZjFmYV8zLTAtMS0xLTEwMTQxNw_64ee7677-2840-423c-a503-1f3932dcbfa3">800 N. Glebe Road</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">,</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="id598b4ef6927435d9f551b05ce16b3bb_D20230503-20230503" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NGIxMTJjYTU3YjQyMDU5YjYwYTlhOWY0ZmY4YTA0L3NlYzo0NDRiMTEyY2E1N2I0MjA1OWI2MGE5YTlmNGZmOGEwNF8xL2ZyYWc6ZTkxNDZhZGU1OWMwNDNmZThhYjIzZTEyNzQ4YjI2MjYvdGFibGU6NmNiNGY4NzAwOGE0NDI1MjlhNGI0Mjg5ODcwY2YxZmEvdGFibGVyYW5nZTo2Y2I0Zjg3MDA4YTQ0MjUyOWE0YjQyODk4NzBjZjFmYV8zLTItMS0xLTEwMTQxNw_76a3d79f-e023-48e6-a460-d0ed396754e1">Suite 500</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">,</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="id598b4ef6927435d9f551b05ce16b3bb_D20230503-20230503" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NGIxMTJjYTU3YjQyMDU5YjYwYTlhOWY0ZmY4YTA0L3NlYzo0NDRiMTEyY2E1N2I0MjA1OWI2MGE5YTlmNGZmOGEwNF8xL2ZyYWc6ZTkxNDZhZGU1OWMwNDNmZThhYjIzZTEyNzQ4YjI2MjYvdGFibGU6NmNiNGY4NzAwOGE0NDI1MjlhNGI0Mjg5ODcwY2YxZmEvdGFibGVyYW5nZTo2Y2I0Zjg3MDA4YTQ0MjUyOWE0YjQyODk4NzBjZjFmYV8zLTQtMS0xLTEwMTQxNw_453d1be8-32cb-42ad-87d4-e98917061360">Arlington</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">,</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="id598b4ef6927435d9f551b05ce16b3bb_D20230503-20230503" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NGIxMTJjYTU3YjQyMDU5YjYwYTlhOWY0ZmY4YTA0L3NlYzo0NDRiMTEyY2E1N2I0MjA1OWI2MGE5YTlmNGZmOGEwNF8xL2ZyYWc6ZTkxNDZhZGU1OWMwNDNmZThhYjIzZTEyNzQ4YjI2MjYvdGFibGU6NmNiNGY4NzAwOGE0NDI1MjlhNGI0Mjg5ODcwY2YxZmEvdGFibGVyYW5nZTo2Y2I0Zjg3MDA4YTQ0MjUyOWE0YjQyODk4NzBjZjFmYV8zLTYtMS0xLTEwMTQxNw_2cdb5849-7875-4bbe-b88e-6435542c206e">Virginia</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">,</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="id598b4ef6927435d9f551b05ce16b3bb_D20230503-20230503" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NGIxMTJjYTU3YjQyMDU5YjYwYTlhOWY0ZmY4YTA0L3NlYzo0NDRiMTEyY2E1N2I0MjA1OWI2MGE5YTlmNGZmOGEwNF8xL2ZyYWc6ZTkxNDZhZGU1OWMwNDNmZThhYjIzZTEyNzQ4YjI2MjYvdGFibGU6NmNiNGY4NzAwOGE0NDI1MjlhNGI0Mjg5ODcwY2YxZmEvdGFibGVyYW5nZTo2Y2I0Zjg3MDA4YTQ0MjUyOWE0YjQyODk4NzBjZjFmYV8zLTgtMS0xLTEwMTQxNw_9543ea6a-ea0a-4b3f-a8dc-4b00055673aa">22203</ix:nonNumeric></span></td></tr><tr style="height:12pt"><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(Address of principal executive offices)(zip code)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">(<ix:nonNumeric contextRef="id598b4ef6927435d9f551b05ce16b3bb_D20230503-20230503" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NGIxMTJjYTU3YjQyMDU5YjYwYTlhOWY0ZmY4YTA0L3NlYzo0NDRiMTEyY2E1N2I0MjA1OWI2MGE5YTlmNGZmOGEwNF8xL2ZyYWc6ZTkxNDZhZGU1OWMwNDNmZThhYjIzZTEyNzQ4YjI2MjYvdGV4dHJlZ2lvbjplOTE0NmFkZTU5YzA0M2ZlOGFiMjNlMTI3NDhiMjYyNl8xNjYz_cfa25127-2ea1-4599-a951-e4561f65e82c">571</ix:nonNumeric>) <ix:nonNumeric contextRef="id598b4ef6927435d9f551b05ce16b3bb_D20230503-20230503" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NGIxMTJjYTU3YjQyMDU5YjYwYTlhOWY0ZmY4YTA0L3NlYzo0NDRiMTEyY2E1N2I0MjA1OWI2MGE5YTlmNGZmOGEwNF8xL2ZyYWc6ZTkxNDZhZGU1OWMwNDNmZThhYjIzZTEyNzQ4YjI2MjYvdGV4dHJlZ2lvbjplOTE0NmFkZTU5YzA0M2ZlOGFiMjNlMTI3NDhiMjYyNl8xNjU3_c8eb53ce-42ae-44b6-8428-1c3275fd6edf">389-6000</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Not Applicable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">(Former name or former address, if changed since last report.)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">_________________________</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="id598b4ef6927435d9f551b05ce16b3bb_D20230503-20230503" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NGIxMTJjYTU3YjQyMDU5YjYwYTlhOWY0ZmY4YTA0L3NlYzo0NDRiMTEyY2E1N2I0MjA1OWI2MGE5YTlmNGZmOGEwNF8xL2ZyYWc6ZTkxNDZhZGU1OWMwNDNmZThhYjIzZTEyNzQ4YjI2MjYvdGV4dHJlZ2lvbjplOTE0NmFkZTU5YzA0M2ZlOGFiMjNlMTI3NDhiMjYyNl8xNjU4_fb336948-ce58-46b9-a41b-aa94c53bfe61">&#9744;</ix:nonNumeric>  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="id598b4ef6927435d9f551b05ce16b3bb_D20230503-20230503" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NGIxMTJjYTU3YjQyMDU5YjYwYTlhOWY0ZmY4YTA0L3NlYzo0NDRiMTEyY2E1N2I0MjA1OWI2MGE5YTlmNGZmOGEwNF8xL2ZyYWc6ZTkxNDZhZGU1OWMwNDNmZThhYjIzZTEyNzQ4YjI2MjYvdGV4dHJlZ2lvbjplOTE0NmFkZTU5YzA0M2ZlOGFiMjNlMTI3NDhiMjYyNl8xNjY0_2baf53eb-66a4-4db4-b826-b1388c9c97ce">&#9744;</ix:nonNumeric>  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="id598b4ef6927435d9f551b05ce16b3bb_D20230503-20230503" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NGIxMTJjYTU3YjQyMDU5YjYwYTlhOWY0ZmY4YTA0L3NlYzo0NDRiMTEyY2E1N2I0MjA1OWI2MGE5YTlmNGZmOGEwNF8xL2ZyYWc6ZTkxNDZhZGU1OWMwNDNmZThhYjIzZTEyNzQ4YjI2MjYvdGV4dHJlZ2lvbjplOTE0NmFkZTU5YzA0M2ZlOGFiMjNlMTI3NDhiMjYyNl8xNjU5_ec94b152-9617-4225-acc3-b138fd44d54a">&#9744;</ix:nonNumeric>  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="id598b4ef6927435d9f551b05ce16b3bb_D20230503-20230503" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NGIxMTJjYTU3YjQyMDU5YjYwYTlhOWY0ZmY4YTA0L3NlYzo0NDRiMTEyY2E1N2I0MjA1OWI2MGE5YTlmNGZmOGEwNF8xL2ZyYWc6ZTkxNDZhZGU1OWMwNDNmZThhYjIzZTEyNzQ4YjI2MjYvdGV4dHJlZ2lvbjplOTE0NmFkZTU5YzA0M2ZlOGFiMjNlMTI3NDhiMjYyNl8xNjY1_6f1c2135-fc09-4b9b-a92b-4405d90f06e1">&#9744;</ix:nonNumeric>  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:510.00pt"><tr><td style="width:1.0pt"></td><td style="width:232.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:85.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:186.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr style="height:24pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id598b4ef6927435d9f551b05ce16b3bb_D20230503-20230503" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NGIxMTJjYTU3YjQyMDU5YjYwYTlhOWY0ZmY4YTA0L3NlYzo0NDRiMTEyY2E1N2I0MjA1OWI2MGE5YTlmNGZmOGEwNF8xL2ZyYWc6ZTkxNDZhZGU1OWMwNDNmZThhYjIzZTEyNzQ4YjI2MjYvdGFibGU6MjU1NzJmMzBlNzYzNGFkNDllMjc5YzM5NTJjYzg3NjEvdGFibGVyYW5nZToyNTU3MmYzMGU3NjM0YWQ0OWUyNzljMzk1MmNjODc2MV8xLTAtMS0xLTEwMTQxNw_c1b4df64-ff3b-40ba-8dfc-b4c544ee8630">Class A Common Stock of Evolent Health, Inc., par value $0.01 per share</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id598b4ef6927435d9f551b05ce16b3bb_D20230503-20230503" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NGIxMTJjYTU3YjQyMDU5YjYwYTlhOWY0ZmY4YTA0L3NlYzo0NDRiMTEyY2E1N2I0MjA1OWI2MGE5YTlmNGZmOGEwNF8xL2ZyYWc6ZTkxNDZhZGU1OWMwNDNmZThhYjIzZTEyNzQ4YjI2MjYvdGFibGU6MjU1NzJmMzBlNzYzNGFkNDllMjc5YzM5NTJjYzg3NjEvdGFibGVyYW5nZToyNTU3MmYzMGU3NjM0YWQ0OWUyNzljMzk1MmNjODc2MV8xLTEtMS0xLTEwMTQxNw_d1a37407-fd9e-4ed6-8b0f-7f434dc11afa">EVH</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id598b4ef6927435d9f551b05ce16b3bb_D20230503-20230503" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NGIxMTJjYTU3YjQyMDU5YjYwYTlhOWY0ZmY4YTA0L3NlYzo0NDRiMTEyY2E1N2I0MjA1OWI2MGE5YTlmNGZmOGEwNF8xL2ZyYWc6ZTkxNDZhZGU1OWMwNDNmZThhYjIzZTEyNzQ4YjI2MjYvdGFibGU6MjU1NzJmMzBlNzYzNGFkNDllMjc5YzM5NTJjYzg3NjEvdGFibGVyYW5nZToyNTU3MmYzMGU3NjM0YWQ0OWUyNzljMzk1MmNjODc2MV8xLTItMS0xLTEwMTQxNw_1366a1c8-d4bc-4c70-90cc-acfaf71209d1">New York Stock Exchange</ix:nonNumeric></span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">Emerging growth company <ix:nonNumeric contextRef="id598b4ef6927435d9f551b05ce16b3bb_D20230503-20230503" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NGIxMTJjYTU3YjQyMDU5YjYwYTlhOWY0ZmY4YTA0L3NlYzo0NDRiMTEyY2E1N2I0MjA1OWI2MGE5YTlmNGZmOGEwNF8xL2ZyYWc6ZTkxNDZhZGU1OWMwNDNmZThhYjIzZTEyNzQ4YjI2MjYvdGV4dHJlZ2lvbjplOTE0NmFkZTU5YzA0M2ZlOGFiMjNlMTI3NDhiMjYyNl8xNjYw_06825aa7-8aa1-4d7c-9c3d-f287c95b7de7">&#9744;</ix:nonNumeric> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div id="i444b112ca57b42059b60a9a9f4ff8a04_7"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Item 2.02.  Results of Operations and Financial Condition</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On May&#160;3, 2023, Evolent Health, Inc. (the "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">") issued a press release announcing its financial results for the quarter ended March&#160;31, 2023, a copy of which is furnished herewith as Exhibit 99.1.  </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The information, including Exhibit 99.1 hereto, furnished under this Item 2.02 shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Exchange Act of 1934, as amended (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exchange Act</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), or otherwise subject the Company or any other person to liability under that Section, to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Exchange Act or the Securities Act of 1933, as amended (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Securities Act</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), except as shall be expressly set forth by specific reference in such a filing.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div id="i444b112ca57b42059b60a9a9f4ff8a04_110"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Item 5.02 - Departure of Directors or Principal Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</span></div><div><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b) In connection with organizational restructuring, the Company is announcing the departure of Steve Tutewohl, Chief Operating Officer.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Mr. Tutewohl&#8217;s departure, effective July 3, 2023, will be treated as an involuntary termination without cause consistent with his existing severance and change-in-control agreement, a form of which was filed as Exhibit 10.32 to the Company&#8217;s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">SEC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">"), on February 26, 2021. Mr. Tutewohl will enter into a customary release of claims. The severance benefits he is entitled to are consistent with a termination without cause, as further described under the heading &#8220;Compensation Discussion and Analysis &#8211; Potential Payments Upon Termination or Change in Control&#8221; in the Company&#8217;s definitive proxy statement on Schedule 14A filed with the SEC on April 28, 2023, except that in lieu of a lump sum cash bonus, Mr. Tutewohl and the Company have agreed that he will receive shares of the Company&#8217;s Class A common stock in an amount equal to such lump sum cash bonus, calculated based on the closing price of the Company&#8217;s Class A common stock on the business day prior to the effective date of his departure.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c) On May 3, 2023, the Company&#8217;s Board of Directors appointed Emily Rafferty to serve as the Company&#8217;s Chief Operating Officer, effective July 3, 2023. Ms. Rafferty, 40, has served as the President and Chief Operating Officer of Evolent Health Services, a former reporting segment of the Company which houses the Company&#8217;s administrative simplification solution and certain supporting population health infrastructure since September 2020. Prior to becoming President and Chief Operating Officer of Evolent Health Services, Ms. Rafferty held multiple leadership roles within the Company including President, Market Operations and Pharmacy Services, as well as Senior Vice President, Advisory Services. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">There are no arrangements or understandings between Ms. Rafferty and any other person pursuant to which she was appointed as an officer of the Company. There are no family relationships between Ms. Rafferty and any director or executive officer of the Company, and she has no direct or indirect material interest in any transaction required to &#8220;be disclosed pursuant to Item 404(a) of Regulation S-K.</span></div><div style="margin-bottom:12pt;text-align:justify"><span><br/></span></div><div id="i444b112ca57b42059b60a9a9f4ff8a04_10"></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Item 9.01.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Financial Statements and Exhibits.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">Exhibits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.833%"><tr><td style="width:1.0%"></td><td style="width:14.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.487%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:82.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Exhibit No.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Description</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="a1q23exhibit991.htm">99.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="a1q23exhibit991.htm">Press Release of Evolent Health, Inc. dated May 3, 2023.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:18pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The cover page from this Current Report on Form 8-K, formatted as Inline XBRL.</span></td></tr></table></div><div id="i444b112ca57b42059b60a9a9f4ff8a04_13"></div><div style="text-align:center"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;     </span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;             </span></div><div style="margin-top:5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:231.00pt"><tr><td style="width:1.0pt"></td><td style="width:82.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:144.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EVOLENT HEALTH, INC.</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;/s/ Jonathan D. Weinberg</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jonathan D. Weinberg</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title:</span></td><td colspan="3" style="padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">General Counsel and Secretary</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date:  May&#160;3, 2023 </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a1q23exhibit991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ifb20f1c2888f4418bede3aa643490273_1"></div><div style="min-height:36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:65.972%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:29pt"><td colspan="3" rowspan="3" style="padding:0 1pt"><div style="text-align:center"><img alt="image0a06.jpg" src="image0a06.jpg" style="height:66px;margin-bottom:5pt;vertical-align:text-bottom;width:280px"></div></td></tr><tr style="height:29pt"><td colspan="3" style="display:none"></td></tr><tr style="height:29pt"><td colspan="3" style="display:none"></td></tr></table></div><div><font><br></font></div><div style="text-align:center"><font style="color:#242d69;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolent Health Announces First Quarter 2023 Results</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">WASHINGTON (May&#160;3, 2023) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8211; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Evolent Health, Inc. (NYSE&#58; EVH), a health care company that delivers proven clinical and administrative solutions to payers and providers, today announced financial results for the quarter ended March&#160;31, 2023. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Highlights from the first quarter 2023 announcement include&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Revenue of $427.7 million, an increase of $130.6 million, or 44.0%, from the three months ended March 31, 2022. </font></div><div style="margin-bottom:3pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Net loss attributable to common shareholders of Evolent Health, Inc. of $26.3 million resulting in a net loss margin of (6.1)%.</font></div><div style="margin-bottom:3pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Adjusted EBITDA of $50.5 million resulting in an Adjusted EBITDA margin of 11.8%. </font></div><div style="margin-bottom:3pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Total Lives on Platform of 65.6&#160;million, up from 17.9&#160;million for the three months ended March 31, 2022</font></div><div style="margin-bottom:3pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.46pt">Composed of 3.2&#160;million lives in our Performance Suite with an average PMPM of $24.66, 60.5&#160;million in our Specialty Technology and Services Suite with an average PMPM of $0.36 and 1.9&#160;million on our Administrative Services platform with an average PMPM of $14.91.</font></div><div style="margin-bottom:3pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.46pt">Average unique members of 41.3&#160;million, up from 15.1&#160;million from the three months ended March 31, 2022. </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">Total cases managed during the quarter for case-based products totaled 15.4&#160;thousand, yielding an average per case revenue of $2,555.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Evolent highlighted the following two commercial arrangements to add to the 2023-year sales cycle, taking the total year-to-date count of new partnerships and significant expansions to four versus its target of six to eight&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">As announced in late March, the Company signed a significant specialty technology and services expansion with Centene whereby they will expand their use of Evolent Health&#8217;s oncology solution across Centene and WellCare Medicare Advantage (&#8220;MA&#8221;) members nationally during 2023&#59; and</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">The Company announced today that a long standing national payer customer has entered into an agreement with AMSURG, a leading Ambulatory Surgery Care (&#8220;ASC&#8221;) chain, to utilize the &#160;&#160;&#160;&#160;Company&#8217;s surgical management solution as the preferred implant provider nationally. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Seth Blackley, Chief Executive Officer, and Co-Founder of Evolent Health stated, &#34;We achieved strong first quarter results and a positive start to 2023. Our revenue growth and Adjusted EBITDA margins give us confidence in our financial outlook for 2023 and year-end 2024 Adjusted EBITDA run-rate target. We welcomed NIA into the Evolent family in January and integration is proceeding as anticipated. Through the discipline of our three core operating priorities, Evolent seeks to continue to strengthen our position in specialty value-based care for years to come.&#8221; </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:103%">Financial Results of Evolent Health, Inc.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our earnings releases, prepared remarks, conference calls, slide presentations and webcasts, we may use or discuss non-GAAP financial measures. Definitions of the non-GAAP financial measures, as well as reconciliations of non-GAAP financial measures to the most directly comparable GAAP financial measures are included in this earnings release. See Financial Statement Presentation and Non-GAAP Financial Measures for more information.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">Reported Results </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Evolent Health, Inc. reported the following results in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;)&#58; </font></div><div style="text-align:justify"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Revenue of $427.7 million and $297.1 million for the three months ended March&#160;31, 2023 and 2022, respectively.</font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Cost of revenue of $310.5 million and $219.7 million for the three months ended March&#160;31, 2023 and 2022, respectively.</font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Selling, general and administrative expenses of $89.7 million and $58.9 million for the three months ended March&#160;31, 2023 and 2022, respectively.</font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Net loss attributable to common shareholders of Evolent Health, Inc. of $(26.3) million and $(5.4) million for the three months ended March&#160;31, 2023 and 2022, respectively.</font></div><div style="padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.46pt">Net loss margin of (6.1)% and (1.8)% for the three months ended March&#160;31, 2023 and 2022, respectively.</font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Loss attributable to common shareholders of Evolent Health, Inc., per basic and diluted share, of $(0.24) and $(0.06) for the three months ended March&#160;31, 2023 and 2022, respectively.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Total cash and cash equivalents was $157.5 million as of March&#160;31, 2023. </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Adjusted Results</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Adjusted cost of revenue of $308.2 million and $218.5 million for the three months ended March&#160;31, 2023 and 2022, respectively.</font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Adjusted selling, general and administrative expenses of $68.9 million and $54.3 million for the three months ended March&#160;31, 2023 and 2022, respectively.</font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Adjusted EBITDA of $50.5 million and $24.3 million for the three months ended March&#160;31, 2023 and 2022, respectively.</font></div><div style="padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.46pt">Adjusted EBITDA margin of 11.8% and 8.2% for the three months ended March&#160;31, 2023 and 2022, respectively.</font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Adjusted income attributable to common shareholders of $22.1 million and $10.4 million for the three months ended March&#160;31, 2023 and 2022, respectively.</font></div><div style="padding-left:90pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Adjusted income per share attributable to common shareholders of $0.21 and $0.12 for the three months ended March&#160;31, 2023 and 2022, respectively.</font></div><div><font><br></font></div><div><font style="color:#242d69;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Business Outlook&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We do not believe we can meaningfully reconcile guidance for non-GAAP Adjusted EBITDA to net income (loss) attributable to common shareholders of Evolent Health, Inc. because the company cannot provide guidance for the more significant reconciling items between net income (loss) attributable to common shareholders of Evolent Health, Inc. and Adjusted EBITDA without unreasonable effort. This is due to the fact that future period non-GAAP guidance includes adjustments for items not indicative of our core operations, and as a result from changes to our business due to acquisitions and other events. Such items may, from time to time, include gain on transfer of membership&#59; loss on repayment&#47;extinguishment of debt&#59; gain from equity method investees, change in fair value of contingent consideration, change in tax receivable agreement liability, other income (expense), repositioning costs, stock-based compensation expense, severance costs, amortization of contract cost assets, strategy and shareholder advisory expenses, acquisition-related costs, loss from discontinued operations, dividends and accretion on Series A Preferred Stock and certain other items the company believes to be non-indicative of its ongoing operations. Such adjustments may be affected by changes in ongoing assumptions, judgements, as well as nonrecurring, unusual or unanticipated charges, expenses or gains (losses) or other items that may not directly correlate to the underlying performance of our business operations. The exact amount of these adjustments are not currently determinable but may be significant.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">Second Quarter 2023 Guidance</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">For the three months ending June 30, 2023, revenue is expected to be in the range of approximately $455 million to $470 million. Adjusted EBITDA is expected to be in the range of approximately $45 million to $49 million.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">Full Year 2023 Guidance </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Company is raising its guidance for revenue and reiterating its previously-stated Adjusted EBITDA guidance for the year ending December 31, 2023, with revenue expected to be in the range of approximately $1.935 billion to $1.965 billion and Adjusted EBITDA expected to be in the range of approximately $180 million to $200 million.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">This &#34;Business Outlook&#34; section contains forward-looking statements, and actual results may differ materially. Factors that may cause actual results to differ materially from our current expectations are set forth below in &#34;Forward Looking Statements - Cautionary Language&#34; and Evolent Health, Inc.'s filings with the Securities and Exchange Commission (&#34;SEC&#34;).</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">Additional Outlook Information</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Cash deployed for software development is expected to be in the range of $35 million - $40 million for the year ended December 31, 2023.</font></div><div><font><br></font></div><div><font style="color:#242d69;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Web and Conference Call Information</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Evolent Health, Inc. will hold a conference call to discuss its first quarter performance this evening, May&#160;3, 2023, at 5&#58;00 p.m., Eastern Time. To listen to a live broadcast via the internet and view the accompanying materials, please visit the Company's Investor Relations website at http&#58;&#47;&#47;ir.evolenthealth.com. PLEASE NOTE&#58; Use the following updated numbers to participate by telephone, dial </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">888.396.8049</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> or </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">416.764.8646</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> for international callers, and use the conference ID #</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">55348964</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. Participants are advised to dial in at least fifteen minutes prior to the call to register. The call will be archived on the company's website for one week and will be available beginning later this evening. Evolent Health invites all interested parties to attend the conference call.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#242d69;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investor Day</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, Chief Executive Officer and Co-Founder Seth Blackley and Evolent's executive team will host an Investor Day for the financial community via webcast and in person in Arlington, VA. on Tuesday, May 23, 2023.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The event will feature presentations from Evolent's executive leadership team on the company's long-term corporate strategy, innovative value-based care solutions, and financial outlook. Management will also host a Q&#38;A session with attendees. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A live audio and visual webcast of this event, along with supporting materials, will be available the day of the event on Evolent's investor relations website at ir.evolenthealth.com&#47;. A replay, presentations and transcript will also be available after the event. An audio playback of the event will be available on Evolent's investor relations website, ir.evolenthealth.com, for 90 days after the call.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The event will be held at the Westin in Arlington (801 N Glebe Rd, Arlington, VA 22203) Tuesday, May 23, 2023, at 10 a.m. Eastern Time and is anticipated to end at approximately 1 p.m. Eastern Time.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#242d69;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">About Evolent Health</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Evolent (NYSE&#58; EVH) specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable. Evolent serves a national base of leading payers and providers and is consistently recognized as a top place to work in health care nationally. Learn more about how Evolent is changing the way health care is delivered by visiting evolenthealth.com.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#242d69;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contacts&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Seth Frank</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Investor Relations</font></div><div><font style="color:#0563c1;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">sfrank&#64;evolenthealth.com</font></div><div><font><br></font></div><div><font style="color:#242d69;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Non-GAAP Financial Measures</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to disclosing financial results that are determined in accordance with GAAP, we present Adjusted Cost of Revenue, Adjusted Selling, General and Administrative Expenses, Adjusted Depreciation and Amortization Expenses, Adjusted Total Operating Expenses, Adjusted Change in the Fair Value of Contingent Consideration, Adjusted Operating Income (Loss), Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Income Attributable to Common Shareholders and Adjusted Income per Common Share Attributable to Common Shareholders, which are all non-GAAP financial measures, as supplemental measures to help investors evaluate our fundamental operational performance.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted Cost of Revenue and Adjusted Selling, General and Administrative Expenses are defined as cost of revenue and selling, general and administrative expenses, respectively, adjusted to exclude the impact of stock-based compensation expenses, severance costs, amortization of contract cost assets recorded as a result of a one-time ASC 606 transition adjustment, acquisition-related costs related to acquisitions and business combinations. Management uses Adjusted Cost of Revenue and Adjusted Selling, General and Administrative Expenses as supplemental performance measures, which are also useful to investors, because they facilitate an understanding of our long-term operational costs while removing </font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the effect of acquisition-related costs, severance and termination payments and non-cash items such as stock-based compensation expenses. Additionally, these supplemental performance measures facilitate understanding a breakdown of our Adjusted Total Operating Expenses. Adjustments for acquisition-related costs incurred generally represent professional service fees and direct expenses related to acquisitions. We do not consider the amount of acquisition-related costs to be a representative component of the day-to-day operating performance of our business.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted Depreciation and Amortization Expenses is defined as depreciation and amortization expenses adjusted to exclude the impact of amortization expenses related to intangible assets acquired through asset acquisitions and business combinations. Management uses Adjusted Depreciation and Amortization Expenses as a supplemental performance measure because it reflects a complete view of the operational results. The measure is also useful to investors because it facilitates understanding a breakdown of our Adjusted Total Operating Expenses.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted Change in the Fair Value of Contingent Consideration is defined as changes in the fair value of contingent consideration adjusted to exclude the impact of contingent consideration related to contingent consideration incurred through asset acquisitions and business combinations. Management uses Adjusted Change in the Fair Value of Contingent Consideration as a supplemental performance measure because it reflects a complete view of the operational results. The measure is also useful to investors because it facilitates understanding a breakdown of our Adjusted Total Operating Expenses.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted Total Operating Expenses is defined as the sum of Adjusted Cost of Revenue, Adjusted Selling, General and Administrative Expenses and Adjusted Depreciation and Amortization Expenses, and reflects the adjustments made in those non-GAAP measures. Adjusted Total Operating Expenses is further adjusted to exclude the impact of (gain) loss on disposal of assets and items arising from acquisitions and business combinations, such as changes in fair value of contingent consideration.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted Operating Income (Loss) is defined as Adjusted Revenue less Adjusted Total Operating Expenses, and reflects the adjustments made in those non-GAAP measures. Management uses Adjusted Total Operating Expenses and Adjusted Operating Income (Loss) because the removal of acquisition costs, severance or non-cash items (e.g. depreciation, amortization and stock-based compensation expenses) allows us to focus on operational performance, and believes these measures are useful to investors because they give investors insight into our core operating performance.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted EBITDA is defined as net loss attributable to common shareholders of Evolent Health, Inc. before interest income, interest expense, benefit from (provision for) income taxes, depreciation and amortization expenses, adjusted to exclude gain from equity method investees, changes in fair value of contingent consideration, change in the tax receivable agreement liability, other income (expense), net, stock-based compensation expense, severance costs, amortization of contract cost assets, dividends and accretion on Series A Preferred Stock and acquisition-related costs. Acquisition-related costs include but are not limited to integration consultants, investor outreach services, external valuation and accounting advisory services, legal fees, dedicated integration employee salaries, bonuses, expenses and related payroll taxes, and transaction bonuses paid to certain employees.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management uses Adjusted EBITDA as a supplemental performance measure because the removal of acquisition-related costs, severance or non-cash items (e.g. depreciation, amortization and stock-based compensation expenses) allows us to focus on operational performance. We believe that this measure is also useful to investors because it allows further insight into the period over period operational performance in a manner that is comparable to other organizations in our industry and in the market in general.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted EBITDA Margin is as defined Adjusted EBITDA divided by Revenue. Management uses Adjusted EBITDA Margin as a supplemental performance measure because it allows the investor to understand operational performance compared to revenues over time. We believe that this measure is also useful to investors because it allows further insight into the period over period operational performance in a manner that is comparable to other organizations in our industry and in the market in general.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted Income Attributable to Common Shareholders is defined as net loss attributable to common shareholders of Evolent Health, Inc. adjusted to exclude gain from equity method investees, provision (benefit) for income taxes, other income (expense), net, changes in fair value of contingent consideration, change in tax receivable agreement liability, purchase accounting adjustments, stock-based compensation expenses, severance costs, amortization of contract cost assets recorded as a result of a one-time ASC 606 transition adjustment, dividends and accretion on Series A Preferred Stock and acquisition-related costs.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted Income per Share Attributable to Common Shareholders is defined as Adjusted Income Attributable to Common Shareholders divided by Weighted-Average Common Shares, and reflects the adjustments made in those non-GAAP measures.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management uses Adjusted Income Attributable to Common Shareholders and Adjusted Income per Share Attributable to Common Shareholders because excluding non-cash items (e.g. depreciation, amortization and stock-based compensation expenses) allows us to focus on operational performance. We believe that these measures are also useful to investors for the same reason.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These adjusted measures do not represent and should not be considered as alternatives to GAAP measurements, and our calculations thereof may not be comparable to similarly entitled measures reported by other companies. A reconciliation of these adjusted measures to their most comparable GAAP financial measures is presented in the tables below. We believe these measures are useful across time in evaluating our fundamental core operating performance.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#242d69;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Lives on Platform and Per Member Per Month (&#8220;PMPM&#8221;) Fee</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance Suite Lives on Platform are calculated by summing monthly members covered for oncology and cardiology specialty care services for contracts not under ASO arrangements, plus members managed by Evolent Care Partners in risk arrangements and divided by the number of months in the period. Specialty Technology and Services Suite Lives on Platform are calculated by summing monthly members covered for oncology, cardiology, musculoskeletal, advanced imaging and other diagnostics specialty care services for contracts under ASO arrangements divided by the number of months in the period. Administrative Services Lives on Platform are calculated by summing monthly members covered for EHS implementation and core performance services divided by the number of months in the period. Cases are calculated by summing the number of individuals receiving services through our IPG and Vital Decisions programs in a given period. Members covered for more than one category are counted in each category. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance Suite Average PMPM fee is defined as revenue pertaining to our Performance Suite during the period reported divided by Performance Suite Lives on Platform for the period divided by the number of months in the period. Specialty Technology and Services Suite Average PMPM fee is defined as revenue pertaining to the Specialty Technology and Services Suite during the period reported divided by Specialty Technology and Services Suite Lives on Platform for the period divided by the number of months in the period. Administrative Services Average PMPM fee is defined as revenue pertaining to the Administrative Services during the period reported divided by the Administrative Services Lives on Platform for the period divided by the number of months in the period. Revenue per Case is calculated by the revenue pertaining to IPG and Vital Decisions divided by the number of cases for a given period.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Average Unique Members are calculated by summing members covered by our Performance Suite, Specialty Technology and Services Suite and Administrative Services. In cases where clients cross between multiple products, we only capture members from the product with the maximum number of members.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management uses Lives on Platform, PMPM fees, Cases, Revenue per Case and Average Unique Members because we believe that they provide insight into the unit economics of our services. We believe that these measures are also useful to investors because they allow further insight into the period over period operational performance. We believe that these measures are also useful to investors because they allow further insight into the period over period operational performance.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has changed its calculation of Lives on Platform to more accurately reflect the membership that corresponds to quarterly revenue.  The Company has recast prior periods to reflect the current presentation of Lives on Platform, PMPM fees, Cases and Revenue per Case.  The current Performance Suite maps to the prior disclosure of the Clinical Solutions Performance Suite. The current Specialty Technology and Services Suite maps to the prior disclosure of the Clinical Solutions New Century Health Technology and Services Suite. The current Administrative Services maps to the prior disclosure of Evolent Health Services segment. There has been no change in the presentation of Cases from prior period.</font></div><div><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5</font></div></div></div><div id="ifb20f1c2888f4418bede3aa643490273_4"></div><hr style="page-break-after:always"><div style="min-height:18pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div id="ifb20f1c2888f4418bede3aa643490273_7"></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Evolent Health, Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Consolidated Statements of Operations and Comprehensive Income (Loss)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited, in thousands, except per share data)</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:489.00pt"><tr><td style="width:1.0pt"></td><td style="width:353.50pt"></td><td style="width:1.0pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0pt"></td><td style="width:63.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:63.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</font></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">427,690&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297,057&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expenses</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310,475&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219,739&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,726&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,932&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization expenses</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,275&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,106&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,569&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,078&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">438,045&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299,855&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,355)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,798)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,060&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,895)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,241)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain from equity method investees</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">423&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">596&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in tax receivable agreement liability</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66,184)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(220)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88,171)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,148)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for (benefit from) income taxes</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68,189)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,202&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before preferred dividends and accretion of Series A Preferred Stock</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,982)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,350)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends and accretion of Series A Preferred Stock</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,276)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common shareholders of Evolent Health, Inc.</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,258)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,350)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss per common share</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted&#58;</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.24)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.06)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-average common shares outstanding</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,783&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,509&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Comprehensive loss</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common shareholders of Evolent Health, Inc.</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,258)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,350)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss, net of taxes, related to&#58;</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(132)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total comprehensive loss attributable to common shareholders of Evolent Health, Inc.</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,202)</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,482)</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6</font></div></div></div><div id="ifb20f1c2888f4418bede3aa643490273_10"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Evolent Health, Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(in thousands, unaudited)</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"></td><td style="width:294.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:112.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:96.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</font></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,519&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188,200&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash and restricted investments</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,451&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,958&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">475,972&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478,054&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">825,857&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">442,784&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,117,945&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">722,774&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,589,459&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,817,293&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,012&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,174&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170,236&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,198&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net of discount</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">632,277&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412,986&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,297,091&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">957,876&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mezzanine equity</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170,625&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total shareholders' equity</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,121,743&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">859,417&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities, mezzanine equity and shareholders' equity</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,589,459&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,817,293&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7</font></div></div></div><div id="ifb20f1c2888f4418bede3aa643490273_13"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Evolent Health, Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Cash Flows</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(in thousands, unaudited)</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"></td><td style="width:388.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:57.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:57.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash and restricted cash used in continuing operations</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash and restricted cash used in operating activities</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,974)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57,442)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash and restricted cash provided by (used in) investing activities</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(394,993)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,766&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash and restricted cash provided by (used in) financing activities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379,729&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51,376)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate on cash and cash equivalents and restricted cash</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(104)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net decrease in cash and cash equivalents and restricted cash</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,188)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(92,156)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents and restricted cash as of beginning-of-period</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215,158&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">354,942&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents and restricted cash as of end-of-period</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,970&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262,786&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8</font></div></div></div><div id="ifb20f1c2888f4418bede3aa643490273_16"></div><hr style="page-break-after:always"><div style="min-height:22.5pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Evolent Health, Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Reconciliation of Adjusted Results of Operations</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(in thousands, unaudited)</font></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="margin-top:5pt;padding-left:9pt;padding-right:9pt;text-align:center;text-indent:-18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:733.50pt"><tr><td style="width:1.0pt"></td><td style="width:106.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:63.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:64.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:51.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:51.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:51.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:51.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31, 2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31, 2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Evolent Health, Inc.<br>as Reported</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Evolent Health, Inc.<br>as Adjusted</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Evolent</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Evolent</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Evolent</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Evolent</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Health, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Health, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Health, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Health, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change Over Prior Period</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change Over Prior Period</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">as Reported</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Adjustments</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">as Adjusted</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">as Reported</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Adjustments</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">as Adjusted</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</font></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Revenue</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">427,690&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">427,690&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">297,057&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">297,057&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">130,633&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44.0&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">130,633&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44.0&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</font></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expenses</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:44pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of revenue (exclusive of depreciation and amortization expenses presented separately below) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">310,475&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,232)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">308,243&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">219,739&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,195)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">218,544&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">90,736&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41.3&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">89,699&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41.0&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</font></td></tr><tr style="height:20pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative expenses </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">89,726&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20,777)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68,949&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58,932&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,674)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54,258&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,794&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52.3&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,691&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.1&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</font></td></tr><tr style="height:20pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization expenses </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29,275&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12,751)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,524&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,106&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,569)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,537&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,169&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">93.8&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,987&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56.8&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</font></td></tr><tr style="height:20pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,569&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8,569)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,078&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,078)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,491&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41.0&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</font></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total operating expenses</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">438,045&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(44,329)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">393,716&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">299,855&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(16,516)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">283,339&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">138,190&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46.1&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">110,377&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39.0&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</font></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating income (loss)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10,355)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,329&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33,974&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,798)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,516&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,718&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7,557)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(270.1)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,256&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">147.7&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:30pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total operating expenses as a percentage of total revenue</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">102.4&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">92.1&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.9&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">95.4&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-top:5pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt">Adjustments to cost of revenue include $1.5 million and $0.8 million in stock-based compensation expense for the three months ended March 31, 2023 and 2022, respectively, and $0.4 million of related to the amortization of contract costs assets for the three months ended March 31, 2022. Adjustments for the three months ended March 31, 2023, include $0.7&#160;million of severance costs.</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt">Adjustments to selling, general and administrative expenses include $9.2 million and $4.5 million in stock-based compensation expense and $11.3&#160;million and $0.5&#160;million of acquisition-related costs resulting from acquisitions and business combinations for the three months ended March 31, 2023 and 2022, respectively. Adjustments for the three months ended March 31, 2023, include $0.3&#160;million of severance costs.</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt">Adjustments to depreciation and amortization expenses of approximately $12.8&#160;million and $4.6&#160;million for the three months ended March 31, 2023 and 2022, respectively, relate to amortization of intangible assets acquired via asset acquisitions and business combinations.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font><br></font></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9</font></div></div></div><div id="ifb20f1c2888f4418bede3aa643490273_22"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div id="ifb20f1c2888f4418bede3aa643490273_25"></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Evolent Health, Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Reconciliation of Adjusted EBITDA to Net Income (Loss)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Attributable to Common Shareholders of Evolent Health, Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands, except per share data)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited)</font></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"></td><td style="width:406.75pt"></td><td style="width:1.0pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:33pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</font></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss attributable to common shareholders of Evolent Health, Inc.</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$(26,258)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$(5,350)</font></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Net loss margin</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(6.1)%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(1.8)%</font></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less&#58;</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,060</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117</font></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,895)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,241)</font></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit from (provision for) income taxes</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,189</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,202)</font></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization expenses</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,275)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,106)</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in tax receivable agreement liability</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66,184)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain from equity method investees</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">423</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">596</font></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration </font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,569)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,078)</font></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(220)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,710)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,346)</font></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance costs</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(954)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</font></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of contract cost assets</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</font></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends and accretion of Series A Preferred Stock</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,276)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition costs </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,346)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(457)</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted EBITDA</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$50,499</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$24,255</font></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted EBITDA margin</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.8%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2%</font></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.65pt">Acquisition-related costs include but are not limited to integration consultants, investor outreach services, external valuation and accounting advisory services, legal fees, dedicated integration employee salaries, bonuses, expenses and related payroll taxes, and transaction bonuses paid to certain employees. </font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">10</font></div></div></div><div id="ifb20f1c2888f4418bede3aa643490273_28"></div><hr style="page-break-after:always"><div style="min-height:27pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Evolent Health, Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Reconciliation of Adjusted Income Attributable to Common</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Shareholders to Net Loss Attributable to Common Shareholders</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands, except per share data)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited)</font></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"></td><td style="width:398.50pt"></td><td style="width:1.0pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0pt"></td><td style="width:52.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:52.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</font></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss attributable to common shareholders of Evolent Health, Inc.</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,258)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,350)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less&#58;</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain from equity method investees</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">423&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">596&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(220)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for (benefit from) income taxes</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,189&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,569)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,078)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in tax receivable agreement liability</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66,184)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase accounting adjustments</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,751)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,569)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,710)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,346)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance costs</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(954)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of contract cost assets</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends and accretion of Series A Preferred Stock</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,276)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related costs</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,346)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(457)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted income attributable to common shareholders</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,140&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,392&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss per share attributable to common shareholders </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic and diluted</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.24)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.06)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted income per share attributable to common shareholders </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic and diluted</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.21&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.12&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-average common shares</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic and diluted</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,783&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,509&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.65pt">For periods of net loss, shares used in both the basic and diluted earnings per share calculation represent basic shares as using diluted shares would be anti-dilutive.</font></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11</font></div></div></div><div id="ifb20f1c2888f4418bede3aa643490273_31"></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORWARD-LOOKING STATEMENTS - CAUTIONARY LANGUAGE</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain statements made in this report and in other written or oral statements made by us or on our behalf are &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995 (&#8220;PSLRA&#8221;). A forward-looking statement is a statement that is not a historical fact and, without limitation, includes any statement that may predict, forecast, indicate or imply future results, performance or achievements, and may contain words like&#58; &#8220;believe,&#8221; &#8220;anticipate,&#8221; &#8220;expect,&#8221; &#8220;estimate,&#8221; &#8220;aim,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; &#8220;plan,&#8221; &#8220;project,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;shall,&#8221; &#8220;may,&#8221; &#8220;might&#8221; and other words or phrases with similar meaning in connection with a discussion of future operating or financial performance. In particular, these include statements relating to our ability to grow our impact significantly throughout this year and beyond, future actions, trends in our businesses, prospective services, new partner additions&#47;expansions, our guidance and business outlook and future performance or financial results, and the closing of pending transactions and the outcome of contingencies, such as legal proceedings. We claim the protection afforded by the safe harbor for forward-looking statements provided by the PSLRA.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These statements are only predictions based on our current expectations and projections about future events. Forward-looking statements involve risks and uncertainties that may cause actual results, level of activity, performance or achievements to differ materially from the results contained in the forward-looking statements.&#160;Risks and uncertainties that may cause actual results to vary materially, some of which are described within the forward-looking statements, include, among others&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">risks relating to our ability to efficiently integrate NIA into our operations&#59; </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the financial information of NIA and the pro forma financial information of NIA may not be indicative of future results or our financial condition&#59; </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the significant portion of revenue we derive from our largest partners, and the potential loss, non-renewal, termination or renegotiation of our relationship or contract with any significant partner, or multiple partners in the aggregate&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to terminate certain leases and recognize impairment charges in connection with our repositioning plan&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">evolution of the healthcare regulatory and political framework&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">uncertainty in the health care regulatory framework, including the potential impact of policy changes&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to offer new and innovative products and services and our ability to keep pace with industry standards, technology and our partners&#8217; needs&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">risks related to completed and future acquisitions, investments, alliances and joint ventures, including our acquisitions of IPG and NIA, which could divert management resources, result in unanticipated costs or dilute our stockholders&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the financial benefits we expect to receive as a result of the sale of certain assets of Passport to Molina Healthcare, Inc. may not be realized&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the growth and success of our partners and certain revenues from our engagements, which are difficult to predict and are subject to factors outside of our control, including governmental funding reductions and other policy changes&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">risks relating to our ability to maintain profitability for our total cost of care and New Century Health&#8217;s performance-based contracts and products, including capitation and risk-bearing contracts&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to effectively manage our growth and maintain an efficient cost structure, and to successfully implement cost cutting measures&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">changes in general economic conditions nationally and regionally in our markets, including increasing inflationary pressures and economic and business conditions and the impact thereof on the economy resulting from public health emergencies, epidemics, pandemics or contagious diseases such as the COVID-19 pandemic&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">risks related to the failure of any bank in which we deposit our funds, which could reduce the amount of cash we have available to meet our cash commitments and make additional investments&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to recover the significant upfront costs in our partner relationships and develop our partner relationships over time&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to attract new partners and successfully capture new opportunities&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the increasing number of risk-sharing arrangements we enter into with our partners could limit or negatively impact our profitability&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to estimate the size of our target markets for our services&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to maintain and enhance our reputation and brand recognition&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">consolidation in the health care industry&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">competition which could limit our ability to maintain or expand market share within our industry&#59;</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">risks related to audits by CMS and other governmental payers and actions, including whistleblower claims under the False Claims Act&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to partner with providers due to exclusivity provisions in our contracts in some of our partner and founder contracts&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">risks related to managing our offshore operations and cost reduction goals&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to contain health care costs, implement increases in premium rates on a timely basis, maintain adequate reserves for policy benefits or maintain cost effective provider agreements&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our dependency on our key personnel, and our ability to attract, hire, integrate and retain key personnel&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the impact of additional goodwill and intangible asset impairments on our results of operations&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our indebtedness, our ability to service our indebtedness, and our ability to obtain additional financing on favorable terms or at all&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to achieve profitability in the future&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the impact of litigation proceedings, government inquiries, reviews, audits or investigations&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">material weaknesses in the future may impact our ability to conclude that our internal control over financial reporting is not effective and we may be unable to produce timely and accurate financial statements&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">restrictions on the manner in which we access personal data and penalties as a result of privacy and data protection laws&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">liabilities and reputational risks related to our ability to safeguard the security and privacy of confidential data&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">data loss or corruption due to failures or errors in our systems and service disruptions at our data centers&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">adequate protection of our intellectual property, including trademarks&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">risks related to legal proceedings related to any alleged infringement, misappropriation or violation of third-party intellectual property rights&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our use of &#8220;open source&#8221; software&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to protect the confidentiality of our trade secrets, know-how and other proprietary information&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our reliance on third parties and licensed technologies&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">restrictions on our ability to use, disclose, de-identify or license data and to integrate third-party technologies&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our reliance on Internet infrastructure, bandwidth providers, data center providers, other third parties and our own systems for providing services to our partners&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our reliance on third-party vendors to host and maintain our technology platform&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our obligations to make material payments to certain of our pre-IPO investors for certain tax benefits we may claim in the future&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to utilize benefits under the tax receivables agreement described herein&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our obligations to make payments under the tax receivables agreement that may be accelerated or may exceed the tax benefits we realize&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the terms of agreements between us and certain of our pre-IPO investors may contain different terms than comparable agreement we may enter into with unaffiliated third parties&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the conditional conversion features of the 2025 convertible notes, which, if triggered, could require us to settle the 2025 convertible notes in cash&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">interest rate risk under the Credit Agreement and the terms of our Series A Preferred Stock&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our debt following the NIA acquisition and our ability to meet our obligations&#59; </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to service our debt and pay dividends on our Series A Preferred Stock&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the potential volatility of our Class A common stock price&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the potential decline of our Class A common stock price if a substantial number of shares are sold or become available for sale, including those issuable upon conversion of our Series A Preferred Stock&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our Series A Preferred Stock has rights, preferences and privileges that are not held by and are preferential to the rights of holders of our Class A common stock, and could in the future substantially dilute the ownership interest of holders of our Class A common stock&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">provisions in our certificate of incorporation and by-laws and provisions of Delaware law that discourage or prevent strategic transactions, including a takeover of us&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the ability of certain of our investors to compete with us without restrictions&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">provisions in our certificate of incorporation which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees&#59; and</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our intention not to pay cash dividends on our Class A common stock.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risks included here are not exhaustive. Although we believe the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance or achievements. Our periodic reports and other documents filed with the SEC include additional factors that could affect our businesses and </font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">financial performance. Moreover, we operate in a rapidly changing and competitive environment. New risk factors emerge from time to time, and it is not possible for management to predict all such risk factors.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, it is not possible to assess the effect of all risk factors on our businesses or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, investors should not place undue reliance on forward-looking statements as a prediction of actual results. In addition, we undertake no obligation to publicly update any forward-looking statements to reflect events or circumstances that occur after the date of this release except to the extent expressly required by law.</font></div><div><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">14</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>evh-20230503.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:48ec9819-1b32-4ab5-9021-0a110d0fc8c7,g:2317c2b5-139d-451b-b061-2d090df0b68c-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:evh="http://www.evolenthealth.com/20230503" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.evolenthealth.com/20230503">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="evh-20230503_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="evh-20230503_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="evh-20230503_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPageCoverPage" roleURI="http://www.evolenthealth.com/role/CoverPageCoverPage">
        <link:definition>0000001 - Document - Cover Page Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>4
<FILENAME>evh-20230503_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:48ec9819-1b32-4ab5-9021-0a110d0fc8c7,g:2317c2b5-139d-451b-b061-2d090df0b68c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CoverPageCoverPage" xlink:type="simple" xlink:href="evh-20230503.xsd#CoverPageCoverPage"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/CoverPageCoverPage" xlink:type="extended" id="i45dbda6230824d2fa9eefb929f13672a_CoverPageCoverPage">
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_ebac4338-605f-40f6-87a5-a4e84f8ea95e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_81a97579-0b25-45f2-aa6c-24c214600be5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ebac4338-605f-40f6-87a5-a4e84f8ea95e" xlink:to="loc_dei_Security12bTitle_81a97579-0b25-45f2-aa6c-24c214600be5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_254a2742-bda1-45e1-ab86-5d4d0055e7b5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ebac4338-605f-40f6-87a5-a4e84f8ea95e" xlink:to="loc_dei_EntityIncorporationStateCountryCode_254a2742-bda1-45e1-ab86-5d4d0055e7b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_12f10020-4bb4-49d1-a544-465366bbc23f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ebac4338-605f-40f6-87a5-a4e84f8ea95e" xlink:to="loc_dei_DocumentType_12f10020-4bb4-49d1-a544-465366bbc23f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_5085193c-28e1-4112-bb34-d20d4b9d0b47" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ebac4338-605f-40f6-87a5-a4e84f8ea95e" xlink:to="loc_dei_EntityRegistrantName_5085193c-28e1-4112-bb34-d20d4b9d0b47" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_62f2e98c-ec6a-4350-a9e1-9c0713428aea" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ebac4338-605f-40f6-87a5-a4e84f8ea95e" xlink:to="loc_dei_CityAreaCode_62f2e98c-ec6a-4350-a9e1-9c0713428aea" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_c236f9c5-f38e-43f5-9fc9-8eac569eb26c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ebac4338-605f-40f6-87a5-a4e84f8ea95e" xlink:to="loc_dei_LocalPhoneNumber_c236f9c5-f38e-43f5-9fc9-8eac569eb26c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_2ed68819-28fc-4f37-a5fa-79e4149dc6ae" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ebac4338-605f-40f6-87a5-a4e84f8ea95e" xlink:to="loc_dei_EntityFileNumber_2ed68819-28fc-4f37-a5fa-79e4149dc6ae" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_504beea6-9911-4636-a4b9-df3adade663d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ebac4338-605f-40f6-87a5-a4e84f8ea95e" xlink:to="loc_dei_EntityTaxIdentificationNumber_504beea6-9911-4636-a4b9-df3adade663d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_46c55b8b-d494-49ac-8a7a-125aa0b81fd4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ebac4338-605f-40f6-87a5-a4e84f8ea95e" xlink:to="loc_dei_EntityAddressAddressLine1_46c55b8b-d494-49ac-8a7a-125aa0b81fd4" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_75859bb9-3c5c-435f-aec5-44aab6eeb3a3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ebac4338-605f-40f6-87a5-a4e84f8ea95e" xlink:to="loc_dei_EntityAddressAddressLine2_75859bb9-3c5c-435f-aec5-44aab6eeb3a3" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_e87c70bb-0d5b-47f9-83e6-52f07a1adb38" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ebac4338-605f-40f6-87a5-a4e84f8ea95e" xlink:to="loc_dei_EntityAddressCityOrTown_e87c70bb-0d5b-47f9-83e6-52f07a1adb38" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_aa1fb2e1-16a2-4c96-b893-e22a24605942" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ebac4338-605f-40f6-87a5-a4e84f8ea95e" xlink:to="loc_dei_EntityAddressStateOrProvince_aa1fb2e1-16a2-4c96-b893-e22a24605942" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_ab618fae-fa34-4732-b0e0-56dfd38f7c43" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ebac4338-605f-40f6-87a5-a4e84f8ea95e" xlink:to="loc_dei_EntityAddressPostalZipCode_ab618fae-fa34-4732-b0e0-56dfd38f7c43" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_e10ab221-522c-49e9-bc3d-1233eba3a226" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ebac4338-605f-40f6-87a5-a4e84f8ea95e" xlink:to="loc_dei_WrittenCommunications_e10ab221-522c-49e9-bc3d-1233eba3a226" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_ee4282a2-a01f-4a59-a6f0-62eb6ad64b70" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ebac4338-605f-40f6-87a5-a4e84f8ea95e" xlink:to="loc_dei_SolicitingMaterial_ee4282a2-a01f-4a59-a6f0-62eb6ad64b70" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_8fdac8ea-b8a1-4d56-a77a-cbe2663e2ab7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ebac4338-605f-40f6-87a5-a4e84f8ea95e" xlink:to="loc_dei_PreCommencementTenderOffer_8fdac8ea-b8a1-4d56-a77a-cbe2663e2ab7" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_ef67b2bd-3276-4c99-8fcc-2bdbf1766d4b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ebac4338-605f-40f6-87a5-a4e84f8ea95e" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_ef67b2bd-3276-4c99-8fcc-2bdbf1766d4b" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_20607ddb-6b9b-4603-977e-3f3217b45fa7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ebac4338-605f-40f6-87a5-a4e84f8ea95e" xlink:to="loc_dei_EntityEmergingGrowthCompany_20607ddb-6b9b-4603-977e-3f3217b45fa7" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_a5d5d46f-b741-4f0a-bea1-475372f238a8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ebac4338-605f-40f6-87a5-a4e84f8ea95e" xlink:to="loc_dei_TradingSymbol_a5d5d46f-b741-4f0a-bea1-475372f238a8" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_3969b133-cc2e-495f-ac33-8699a8f3b771" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ebac4338-605f-40f6-87a5-a4e84f8ea95e" xlink:to="loc_dei_SecurityExchangeName_3969b133-cc2e-495f-ac33-8699a8f3b771" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_26a5ec55-e7eb-4293-a966-f312ee2fd8a4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ebac4338-605f-40f6-87a5-a4e84f8ea95e" xlink:to="loc_dei_DocumentPeriodEndDate_26a5ec55-e7eb-4293-a966-f312ee2fd8a4" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_5a1935c2-965d-4d7c-892d-ea6fe56ced1e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ebac4338-605f-40f6-87a5-a4e84f8ea95e" xlink:to="loc_dei_EntityCentralIndexKey_5a1935c2-965d-4d7c-892d-ea6fe56ced1e" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_54693af3-0ec3-433d-bc19-883e2dbedaf8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ebac4338-605f-40f6-87a5-a4e84f8ea95e" xlink:to="loc_dei_AmendmentFlag_54693af3-0ec3-433d-bc19-883e2dbedaf8" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_9af8784b-b818-458e-9ebe-2e1cb2652c4b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_ebac4338-605f-40f6-87a5-a4e84f8ea95e" xlink:to="loc_dei_DocumentInformationTable_9af8784b-b818-458e-9ebe-2e1cb2652c4b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationDocumentAxis_cefa470b-b356-4768-a6c7-9700c8f19ba8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationDocumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_9af8784b-b818-458e-9ebe-2e1cb2652c4b" xlink:to="loc_dei_DocumentInformationDocumentAxis_cefa470b-b356-4768-a6c7-9700c8f19ba8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentDomain_cefa470b-b356-4768-a6c7-9700c8f19ba8_default" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_DocumentInformationDocumentAxis_cefa470b-b356-4768-a6c7-9700c8f19ba8" xlink:to="loc_dei_DocumentDomain_cefa470b-b356-4768-a6c7-9700c8f19ba8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentDomain_a25c4b7d-501b-4904-b7e9-ef81e6072b28" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_DocumentInformationDocumentAxis_cefa470b-b356-4768-a6c7-9700c8f19ba8" xlink:to="loc_dei_DocumentDomain_a25c4b7d-501b-4904-b7e9-ef81e6072b28" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>evh-20230503_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:48ec9819-1b32-4ab5-9021-0a110d0fc8c7,g:2317c2b5-139d-451b-b061-2d090df0b68c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_DocumentPeriodEndDate_a4daca94-bc02-4504-896f-2c31109912c7_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_53656907-1811-4aca-ae58-722b380e9494_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_b9dfc457-21cc-489f-be04-5dfce1555cc2_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_10c5a234-aa34-4641-ad6d-e5703f90bec6_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_65282bca-8ae2-41fe-b526-eb7b97d56884_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_313729b5-5a11-44b6-a058-020250a8b0e0_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentDomain_1ff8f765-2fb4-43ce-ba61-80ded51ba428_terseLabel_en-US" xlink:label="lab_dei_DocumentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document [Domain]</link:label>
    <link:label id="lab_dei_DocumentDomain_label_en-US" xlink:label="lab_dei_DocumentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentDomain" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentDomain" xlink:to="lab_dei_DocumentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_ede330a8-483a-4da3-ac49-5ca548e80649_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_f80aff0c-9377-468f-b8ea-f9f02009a2a7_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_47f81351-29a2-4983-b3e3-b3f17d56bfe4_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_8d010f35-cc67-4daa-88c3-f7d80c21b17f_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationLineItems_c3633706-f961-452a-862e-536f8a9db95e_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:label id="lab_dei_DocumentInformationLineItems_label_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="lab_dei_DocumentInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_e4feead8-f043-40ce-9c42-b02715768821_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_726de7fa-10dc-42eb-9b7c-43b42e6ff519_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_5c2915b8-1660-4d31-ba16-6cc45f110573_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_919322c8-84e1-4b11-ba9e-1462c3729983_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_3ac7508c-1df2-4b13-a075-9c5e2e0cd9ba_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_c66c10e9-c6dc-4121-9885-f913e4decb3e_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_2cab5be0-d10b-4f83-a7ae-df343e5b84fd_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationDocumentAxis_ecb39bfa-e92c-4a8e-8633-be0a5f91c149_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationDocumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information, Document [Axis]</link:label>
    <link:label id="lab_dei_DocumentInformationDocumentAxis_label_en-US" xlink:label="lab_dei_DocumentInformationDocumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information, Document [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationDocumentAxis" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationDocumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationDocumentAxis" xlink:to="lab_dei_DocumentInformationDocumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_90057cf7-ca47-4557-b976-91e5d1a2111a_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_c539d858-9f4d-4b4d-bf4b-49de40724add_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationTable_bea1514f-cfcf-4e42-8483-754b6ca55512_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Table]</link:label>
    <link:label id="lab_dei_DocumentInformationTable_label_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable" xlink:to="lab_dei_DocumentInformationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_87adb40b-366b-40e1-89bc-86dd257d9f61_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_5dbc0414-0218-4d76-980a-3643c01d3a93_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_e9d0b499-ca8c-4e07-b224-78d22de9c291_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_9c7a088b-e758-490c-9052-35b395bd84b0_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_ff584fa5-c37b-486e-bed0-9aa6cd3c29f5_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>evh-20230503_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:48ec9819-1b32-4ab5-9021-0a110d0fc8c7,g:2317c2b5-139d-451b-b061-2d090df0b68c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CoverPageCoverPage" xlink:type="simple" xlink:href="evh-20230503.xsd#CoverPageCoverPage"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/CoverPageCoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_d42ddb02-f399-41ac-a694-8ee541d10d55" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_9af8784b-b818-458e-9ebe-2e1cb2652c4b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d42ddb02-f399-41ac-a694-8ee541d10d55" xlink:to="loc_dei_DocumentInformationTable_9af8784b-b818-458e-9ebe-2e1cb2652c4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationDocumentAxis_cefa470b-b356-4768-a6c7-9700c8f19ba8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationDocumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_9af8784b-b818-458e-9ebe-2e1cb2652c4b" xlink:to="loc_dei_DocumentInformationDocumentAxis_cefa470b-b356-4768-a6c7-9700c8f19ba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentDomain_a25c4b7d-501b-4904-b7e9-ef81e6072b28" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationDocumentAxis_cefa470b-b356-4768-a6c7-9700c8f19ba8" xlink:to="loc_dei_DocumentDomain_a25c4b7d-501b-4904-b7e9-ef81e6072b28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_ebac4338-605f-40f6-87a5-a4e84f8ea95e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_9af8784b-b818-458e-9ebe-2e1cb2652c4b" xlink:to="loc_dei_DocumentInformationLineItems_ebac4338-605f-40f6-87a5-a4e84f8ea95e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_81a97579-0b25-45f2-aa6c-24c214600be5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ebac4338-605f-40f6-87a5-a4e84f8ea95e" xlink:to="loc_dei_Security12bTitle_81a97579-0b25-45f2-aa6c-24c214600be5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_254a2742-bda1-45e1-ab86-5d4d0055e7b5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ebac4338-605f-40f6-87a5-a4e84f8ea95e" xlink:to="loc_dei_EntityIncorporationStateCountryCode_254a2742-bda1-45e1-ab86-5d4d0055e7b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_12f10020-4bb4-49d1-a544-465366bbc23f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ebac4338-605f-40f6-87a5-a4e84f8ea95e" xlink:to="loc_dei_DocumentType_12f10020-4bb4-49d1-a544-465366bbc23f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_5085193c-28e1-4112-bb34-d20d4b9d0b47" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ebac4338-605f-40f6-87a5-a4e84f8ea95e" xlink:to="loc_dei_EntityRegistrantName_5085193c-28e1-4112-bb34-d20d4b9d0b47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_62f2e98c-ec6a-4350-a9e1-9c0713428aea" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ebac4338-605f-40f6-87a5-a4e84f8ea95e" xlink:to="loc_dei_CityAreaCode_62f2e98c-ec6a-4350-a9e1-9c0713428aea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_c236f9c5-f38e-43f5-9fc9-8eac569eb26c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ebac4338-605f-40f6-87a5-a4e84f8ea95e" xlink:to="loc_dei_LocalPhoneNumber_c236f9c5-f38e-43f5-9fc9-8eac569eb26c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_2ed68819-28fc-4f37-a5fa-79e4149dc6ae" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ebac4338-605f-40f6-87a5-a4e84f8ea95e" xlink:to="loc_dei_EntityFileNumber_2ed68819-28fc-4f37-a5fa-79e4149dc6ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_504beea6-9911-4636-a4b9-df3adade663d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ebac4338-605f-40f6-87a5-a4e84f8ea95e" xlink:to="loc_dei_EntityTaxIdentificationNumber_504beea6-9911-4636-a4b9-df3adade663d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_46c55b8b-d494-49ac-8a7a-125aa0b81fd4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ebac4338-605f-40f6-87a5-a4e84f8ea95e" xlink:to="loc_dei_EntityAddressAddressLine1_46c55b8b-d494-49ac-8a7a-125aa0b81fd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_75859bb9-3c5c-435f-aec5-44aab6eeb3a3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ebac4338-605f-40f6-87a5-a4e84f8ea95e" xlink:to="loc_dei_EntityAddressAddressLine2_75859bb9-3c5c-435f-aec5-44aab6eeb3a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_e87c70bb-0d5b-47f9-83e6-52f07a1adb38" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ebac4338-605f-40f6-87a5-a4e84f8ea95e" xlink:to="loc_dei_EntityAddressCityOrTown_e87c70bb-0d5b-47f9-83e6-52f07a1adb38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_aa1fb2e1-16a2-4c96-b893-e22a24605942" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ebac4338-605f-40f6-87a5-a4e84f8ea95e" xlink:to="loc_dei_EntityAddressStateOrProvince_aa1fb2e1-16a2-4c96-b893-e22a24605942" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_ab618fae-fa34-4732-b0e0-56dfd38f7c43" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ebac4338-605f-40f6-87a5-a4e84f8ea95e" xlink:to="loc_dei_EntityAddressPostalZipCode_ab618fae-fa34-4732-b0e0-56dfd38f7c43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_e10ab221-522c-49e9-bc3d-1233eba3a226" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ebac4338-605f-40f6-87a5-a4e84f8ea95e" xlink:to="loc_dei_WrittenCommunications_e10ab221-522c-49e9-bc3d-1233eba3a226" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_ee4282a2-a01f-4a59-a6f0-62eb6ad64b70" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ebac4338-605f-40f6-87a5-a4e84f8ea95e" xlink:to="loc_dei_SolicitingMaterial_ee4282a2-a01f-4a59-a6f0-62eb6ad64b70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_8fdac8ea-b8a1-4d56-a77a-cbe2663e2ab7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ebac4338-605f-40f6-87a5-a4e84f8ea95e" xlink:to="loc_dei_PreCommencementTenderOffer_8fdac8ea-b8a1-4d56-a77a-cbe2663e2ab7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_ef67b2bd-3276-4c99-8fcc-2bdbf1766d4b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ebac4338-605f-40f6-87a5-a4e84f8ea95e" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_ef67b2bd-3276-4c99-8fcc-2bdbf1766d4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_20607ddb-6b9b-4603-977e-3f3217b45fa7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ebac4338-605f-40f6-87a5-a4e84f8ea95e" xlink:to="loc_dei_EntityEmergingGrowthCompany_20607ddb-6b9b-4603-977e-3f3217b45fa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_a5d5d46f-b741-4f0a-bea1-475372f238a8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ebac4338-605f-40f6-87a5-a4e84f8ea95e" xlink:to="loc_dei_TradingSymbol_a5d5d46f-b741-4f0a-bea1-475372f238a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_3969b133-cc2e-495f-ac33-8699a8f3b771" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ebac4338-605f-40f6-87a5-a4e84f8ea95e" xlink:to="loc_dei_SecurityExchangeName_3969b133-cc2e-495f-ac33-8699a8f3b771" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_26a5ec55-e7eb-4293-a966-f312ee2fd8a4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ebac4338-605f-40f6-87a5-a4e84f8ea95e" xlink:to="loc_dei_DocumentPeriodEndDate_26a5ec55-e7eb-4293-a966-f312ee2fd8a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_5a1935c2-965d-4d7c-892d-ea6fe56ced1e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ebac4338-605f-40f6-87a5-a4e84f8ea95e" xlink:to="loc_dei_EntityCentralIndexKey_5a1935c2-965d-4d7c-892d-ea6fe56ced1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_54693af3-0ec3-433d-bc19-883e2dbedaf8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ebac4338-605f-40f6-87a5-a4e84f8ea95e" xlink:to="loc_dei_AmendmentFlag_54693af3-0ec3-433d-bc19-883e2dbedaf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image0a06.jpg
<TEXT>
begin 644 image0a06.jpg
M_]C_X0^"17AI9@  34T *@    @ !P$2  ,    !  $   $:  4    !
M8@$;  4    !    :@$H  ,    !  (   $Q  (    D    <@$R  (    4
M    EH=I  0    !    K    -@ +<;    G$  MQL   "<0061O8F4@4&AO
M=&]S:&]P($-#(#(P,3<@*$UA8VEN=&]S:"D ,C Q-SHP,SHQ,B Q-#HP-3HS
M,0     #H $  P    $  0  H ( !     $   0:H , !     $   #Z
M      8! P #     0 &   !&@ %     0   28!&P %     0   2X!*  #
M     0 "   " 0 $     0   38" @ $     0  #D0         2     $
M  !(     ?_8_^T #$%D;V)E7T--  '_[@ .061O8F4 9(     !_]L A  ,
M" @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,
M# P,# P,# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,
M#!$1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1"  F
M * # 2(  A$! Q$!_]T !  *_\0!/P   04! 0$! 0$          P ! @0%
M!@<("0H+ 0 !!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%
M!P8(!0,,,P$  A$#!"$2,05!46$3(G&!,@84D:&Q0B,D%5+!8C,T<H+10P<E
MDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-UX_-&)Y2DA;25Q-3D
M]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$  @(! @0$ P0%!@<'
M!@4U 0 "$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D8N%R@I)#4Q5C<S3Q
M)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4I(6TE<34Y/2EM<75
MY?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H # ,!  (1 Q$ /P#T/J_UBZ+T
M1K'=3RV8YL^A7J^QW\IE%0LN<W^7Z:%TCZU_5[K5IHZ=FLMO:)]%P=581^\R
MK(9598UOYVQ>2U]5Z/G_ %BR.J_6A]KL.YSWBJN27:[<7%+F.8^NBBC]Q_YG
M\NQ#Z]U+ZM5YU&?]4[+,4TS8:[)'IW,(=390ZU]CMMOO;;5]#_MU61RXV]7%
M7S?H+>)]=9];OJZ_JO['&8!U#U#1Z#F6-/J-!=LWOK;5^;[/?^D_,5SJG5NG
M](Q#F]1N&/CM<UA>07>YQVL:&UA[W?YJ\R^OU5M.?TOZUX+=G[1JIR!&H&30
M&9%&X_1_2T>FS_T%5G_&5US]J,Z-@X =8W)J9GLKC5SL@>AT]G]9V_(31A!,
M*NI7Q>'#\RN+=] P.O=(ZAT]_4\7):<&LN#\AX=4P;/YPEV0VKV,_P!)]!99
M_P 8GU-%GI_M$<QO%5Q9_P!O"GT=O\O>N'^O;;NET])^J6.X?9\7&KML&H;;
MD6V/J]6W^2VZNV[_ *__ ,&Q=4/\5OU>_9OV<NN.=M_Y0WNW;_W_ +-O^R^G
MN_P/I_S?^$]3]*E[>, &1E4CZ:_=_K*L]'KL?(Q\FEF1C6LOIL$LMK<'L</%
MCV2UR\I_Q2_^**__ ,(O_P#/U"M?XK<_+Q>MY?1+732]EECF"2UM]%C*+7U?
MNMN:_P!__%5*G_BJL;5US*M=]&OI]CC'@+:7)PAP1RQWTC2+LA](ZQ]9NA=$
M+&]3RV466#<RH!S["-1O]&EMENSV_P YLV)NC_6CH/6WOKZ9F,OMK&YU)#J[
M WC?Z-[:[?3]WT]FQ>0=+ZET/+ZO=U;ZW/MN9DCU357N/J6.^@RQ[7LL9C8M
M/LII:_\ T?\ @Z_3LCU;JW0,/K%'5/JG990RB+13:2-EK#[F5.>]UC\?*J]E
MM.[_ $GYEGIL7W<;>KBKYO\ )IXGV#JOUKZ!T?+9A=1RQ1DV,;8RO98Z6O<Z
MICIJK>WW65O5?-^O7U4P<Q^%D]0:V^IVRT-98]K'#Z3++JJWTL<S_"?I/T7^
M$7 _XT;/4^LF,^L_SF!06$_RKLK:?^DK_P!<OJ)T?H?U=;GX#K1D8SZV6NL>
M7"T6/;2XNK/Z.I[7V>HWT&UH#%CJ'$3<^W=5G7P>L^M_UBHZ9]7K,G%RVU9.
M76?V;:P>H'OV^K7Z;MMM.U[/S[/T:Y_ZE?7RMU5U/UCZEOR[<AC,1KJH):X,
M8/Z)2VOW7N_/69@X>/G_ .*^^_*:7V=(?DNPB'%H8=V[Z+3ML;^E?[+%/_%U
M]6ND=8HR<O/J?9?AY3/0<VQ[ -K:[VRRMS6/_2_OH\$(PGQ6>&56-U6;#ZBL
MGJG6VXMOV3' LR=-Q/T63]&?WK'?N*[U'+&#@7Y9$^C6YX![D#V-_M.7F'4\
M[*;TW(?476Y>014TLU>ZR]PK=LC_  C][MBHYN,B,,9X99)<'%^[_+B8LV?A
MG'&/FE^3>ZG]=KS8^G#MWAA(LRGZMD?2&/5_,[&_Z9__ %O]]5<;ZP]3>[<W
M.L+@?S7@#_,;[5U/U4^HF#TG'JR.H5LRNI%H+BX!U=)Y]/&8?;^C_P"Y'\Z_
M_@Z_T2U^L_5SI76:B,JH-O\ S,E@#;6D?1]_Y[/^#L_1J:&/EL(J&&.67Z67
M+4LD_P##G&:#RTLLOUF>>*/^K''P_P"![F)Q^B_6ZPO;C]3(+7:-R0 T@_\
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MOIL:UM/^E]C%WE77NO?LW-ZID8>(W&P69DMKOL=8ZS#==0YL.Q:V>E;=C/\
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M]4]/T_YS=ZN/NV_REXZDG8]_TOF_1_[I!?JI8/UJJ^K]N/77U:[[/:Z?L]K
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M!"4      ! _+?LY\T/^ %S[3K)C"5B_.$))300Z      #U    $     $
M      MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M
M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP
M<FEN=&5R3F%M951%6%0    ) %( 10!$ %, 2P!) $X 4P      #W!R:6YT
M4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T '4 <
M"G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT:6Y0<F]O9@
M  EP<F]O9D--64L .$))300[      (M    $     $      !)P<FEN=$]U
M='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R8F]O;
M4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;       3&)L<V)O
M;VP      $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O;VP
M $)C:V=/8FIC     0       %)'0D,    #     %)D("!D;W5B0&_@
M        1W)N(&1O=6) ;^            !";" @9&]U8D!OX
M $)R9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
M     %)S;'15;G1&(U!X;$!RP           "G9E8W1O<D1A=&%B;V]L 0
M  !09U!S96YU;0    !09U!S     %!G4$,     3&5F=%5N=$8C4FQT
M            5&]P(%5N=$8C4FQT                4V-L(%5N=$8C4')C
M0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T
M0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P         -8W)O
M<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P      .$))
M30/M       0 2P    !  $!+     $  3A"24T$)@      #@
M   _@   .$))300-       $    'CA"24T$&0      !    !XX0DE- _,
M      D           $ .$))32<0       *  $          3A"24T#]0
M    2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R
M 0!:    !@       0 U     0 M    !@       3A"24T#^       <
M_____________________________P/H     /______________________
M______\#Z     #_____________________________ ^@     ________
M_____________________P/H   X0DE-! @      !     !   "0    D
M    .$))300>       $     #A"24T$&@     #30    8
M /H   0:    # !% %8 2  M $P ;P!G &\ +0!2 $< 0@    $
M                 0             $&@   /H
M 0                         0     0       &YU;&P    "    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M $QE9G1L;VYG          !"=&]M;&]N9P   /H     4F=H=&QO;F<   0:
M    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '
M<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE
M;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E
M;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   #Z     %)G:'1L;VYG   $&@    -U<FQ415A4
M 0       &YU;&Q415A4     0       $US9V5415A4     0      !F%L
M=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL
M5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z
M06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E
M<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI
M8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M"FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M  MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M #A"24T$%       !     (X0DE-! P     #F     !    H    "8   '@
M  !'0   #D0 &  !_]C_[0 ,061O8F5?0TT  ?_N  Y!9&]B90!D@     '_
MVP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,$0P,# P,
M# P,# P,# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4% X.#@X4
M$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,#/_
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MNVP:AMN1;8^KU;?Y+;J[;O\ K_\ P;%U0_Q6_5[]F_9RZXYVW_E#>[=O_?\
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M\A[JD[CQ9 3#TF!J>/\ =O8LDN6YGD\L<.:8SXLL>/EN9C_E /FA/^OP^O\
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MFYS-^X;XK_KU_P W@]/"_P#_V3A"24T$(0      70    $!    #P!! &0
M;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <    !< 00!D &\ 8@!E "  4 !H
M &\ = !O ', : !O '  ( !# $, (  R #  ,0 W     0 X0DE-! 8
M  < " $!  $! /_A'=!H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O #P_
M>'!A8VME="!B96=I;CTB[[N_(B!I9#TB5S5-,$UP0V5H:4AZ<F53>DY48WIK
M8SED(C\^(#QX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z;65T82\B('@Z
M>&UP=&L](D%D;V)E(%A-4"!#;W)E(#4N-BUC,3,X(#<Y+C$U.3@R-"P@,C Q
M-B\P.2\Q-"TP,3HP.3HP,2 @(" @(" @(CX@/')D9CI21$8@>&UL;G,Z<F1F
M/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R+S(R+7)D9BUS>6YT87@M;G,C
M(CX@/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(@>&UL;G,Z9&,](FAT
M=' Z+R]P=7)L+F]R9R]D8R]E;&5M96YT<R\Q+C$O(B!X;6QN<SIX;7 ](FAT
M=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\B('AM;&YS.GAM<$U-/2)H='1P
M.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O;6TO(B!X;6QN<SIS=%)E9CTB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(@
M>&UL;G,Z<W1%=G0](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP
M92]297-O=7)C945V96YT(R(@>&UL;G,Z:6QL=7-T<F%T;W(](FAT=' Z+R]N
M<RYA9&]B92YC;VTO:6QL=7-T<F%T;W(O,2XP+R(@>&UL;G,Z>&UP5%!G/2)H
M='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O="]P9R\B('AM;&YS.G-T1&EM
M/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O1&EM96YS:6]N
M<R,B('AM;&YS.GAM<$<](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]G
M+R(@>&UL;G,Z<&1F/2)H='1P.B\O;G,N861O8F4N8V]M+W!D9B\Q+C,O(B!X
M;6QN<SIP:&]T;W-H;W ](FAT=' Z+R]N<RYA9&]B92YC;VTO<&AO=&]S:&]P
M+S$N,"\B(&1C.F9O<FUA=#TB:6UA9V4O:G!E9R(@>&UP.DUE=&%D871A1&%T
M93TB,C Q-RTP,RTQ,E0Q-#HP-3HS,2TP-#HP,"(@>&UP.DUO9&EF>41A=&4]
M(C(P,3<M,#,M,3)4,30Z,#4Z,S$M,#0Z,# B('AM<#I#<F5A=&5$871E/2(R
M,#$W+3 R+3$V5#$T.C$P.C S+3 U.C P(B!X;7 Z0W)E871O<E1O;VP](D%D
M;V)E($EL;'5S=')A=&]R($-#(#(P,3<@*$UA8VEN=&]S:"DB('AM<$U-.DEN
M<W1A;F-E240](GAM<"YI:60Z-C!B-C(W-C0M,F(P9"TT-V4S+3EC,F$M-S1E
M-F,T.3-B-68W(B!X;7!-33I$;V-U;65N=$E$/2)A9&]B93ID;V-I9#IP:&]T
M;W-H;W Z930T8C@R8F0M-#=D8RTQ,3=A+6$Y8V,M.#4R,#DR8V4Q8S=B(B!X
M;7!-33I/<FEG:6YA;$1O8W5M96YT240](G5U:60Z-40R,#@Y,C0Y,T)&1$(Q
M,3DQ-$$X-3DP1#,Q-3 X0S@B('AM<$U-.E)E;F1I=&EO;D-L87-S/2)P<F]O
M9CIP9&8B(&EL;'5S=')A=&]R.E-T87)T=7!0<F]F:6QE/2)0<FEN="(@>&UP
M5%!G.DAA<U9I<VEB;&5/=F5R<')I;G0](D9A;'-E(B!X;7!44&<Z2&%S5FES
M:6)L951R86YS<&%R96YC>3TB1F%L<V4B('AM<%109SI.4&%G97,](C$B('!D
M9CI0<F]D=6-E<CTB061O8F4@4$1&(&QI8G)A<GD@,3 N,#$B('!H;W1O<VAO
M<#I#;VQO<DUO9&4](C,B('!H;W1O<VAO<#I)0T-0<F]F:6QE/2)S4D="($E%
M0S8Q.38V+3(N,2(^(#QD8SIT:71L93X@/')D9CI!;'0^(#QR9&8Z;&D@>&UL
M.FQA;F<](G@M9&5F875L="(^179O;&5N="!,;V=O(%8S+7-I;7!L93PO<F1F
M.FQI/B \+W)D9CI!;'0^(#PO9&,Z=&ET;&4^(#QX;7!-33I$97)I=F5D1G)O
M;2!S=%)E9CII;G-T86YC94E$/2)X;7 N:6ED.C0V,S@T-&,Q+3@Q-S,M-&4X
M92TY.65C+3(X8C9E,F(U.&(Y9"(@<W12968Z9&]C=6UE;G1)1#TB>&UP+F1I
M9#HP,S)E,F0W9"TV9C,U+31A8C8M83<X.2TY,CAE,F(W-&9B.60B('-T4F5F
M.F]R:6=I;F%L1&]C=6UE;G1)1#TB=75I9#HU1#(P.#DR-#DS0D9$0C$Q.3$T
M03@U.3!$,S$U,#A#."(@<W12968Z<F5N9&ET:6]N0VQA<W,](G!R;V]F.G!D
M9B(O/B \>&UP34TZ2&ES=&]R>3X@/')D9CI397$^(#QR9&8Z;&D@<W1%=G0Z
M86-T:6]N/2)S879E9"(@<W1%=G0Z:6YS=&%N8V5)1#TB>&UP+FEI9#I&.$8X
M,#-!-#E$,C(V.#$Q.#(R048W,44S,S@R,3 S0R(@<W1%=G0Z=VAE;CTB,C Q
M-RTP,2TS,%0Q-SHQ-3HS,2TP-CHP,"(@<W1%=G0Z<V]F='=A<F5!9V5N=#TB
M061O8F4@26QL=7-T<F%T;W(@0U,V("A-86-I;G1O<V@I(B!S=$5V=#IC:&%N
M9V5D/2(O(B\^(#QR9&8Z;&D@<W1%=G0Z86-T:6]N/2)S879E9"(@<W1%=G0Z
M:6YS=&%N8V5)1#TB>&UP+FEI9#IF-V4Q-# W,"UD86(Y+30T9&(M.&$Q82TX
M-&0R,S%C93<Q86,B('-T179T.G=H96X](C(P,3<M,#(M,394,30Z,3 Z,#,M
M,#4Z,# B('-T179T.G-O9G1W87)E06=E;G0](D%D;V)E($EL;'5S=')A=&]R
M($-#(#(P,3<@*$UA8VEN=&]S:"DB('-T179T.F-H86YG960](B\B+SX@/')D
M9CIL:2!S=$5V=#IA8W1I;VX](F-O;G9E<G1E9"(@<W1%=G0Z<&%R86UE=&5R
M<STB9G)O;2!A<'!L:6-A=&EO;B]P;W-T<V-R:7!T('1O(&EM86=E+V5P<V8B
M+SX@/')D9CIL:2!S=$5V=#IA8W1I;VX](G-A=F5D(B!S=$5V=#II;G-T86YC
M94E$/2)X;7 N:6ED.C0S8S@Y.6$T+64R-F8M-#)C82TX.&)E+3AF83!A,CDX
M,F(U,"(@<W1%=G0Z=VAE;CTB,C Q-RTP,RTQ,E0Q-#HP-3HR,RTP-#HP,"(@
M<W1%=G0Z<V]F='=A<F5!9V5N=#TB061O8F4@4&AO=&]S:&]P($-#(#(P,3<@
M*$UA8VEN=&]S:"DB('-T179T.F-H86YG960](B\B+SX@/')D9CIL:2!S=$5V
M=#IA8W1I;VX](F-O;G9E<G1E9"(@<W1%=G0Z<&%R86UE=&5R<STB9G)O;2!A
M<'!L:6-A=&EO;B]P;W-T<V-R:7!T('1O(&EM86=E+W!N9R(O/B \<F1F.FQI
M('-T179T.F%C=&EO;CTB9&5R:79E9"(@<W1%=G0Z<&%R86UE=&5R<STB8V]N
M=F5R=&5D(&9R;VT@:6UA9V4O97!S9B!T;R!I;6%G92]P;F<B+SX@/')D9CIL
M:2!S=$5V=#IA8W1I;VX](G-A=F5D(B!S=$5V=#II;G-T86YC94E$/2)X;7 N
M:6ED.C S,F4R9#=D+39F,S4M-&%B-BUA-S@Y+3DR.&4R8C<T9F(Y9"(@<W1%
M=G0Z=VAE;CTB,C Q-RTP,RTQ,E0Q-#HP-3HR,RTP-#HP,"(@<W1%=G0Z<V]F
M='=A<F5!9V5N=#TB061O8F4@4&AO=&]S:&]P($-#(#(P,3<@*$UA8VEN=&]S
M:"DB('-T179T.F-H86YG960](B\B+SX@/')D9CIL:2!S=$5V=#IA8W1I;VX]
M(G-A=F5D(B!S=$5V=#II;G-T86YC94E$/2)X;7 N:6ED.C0V,S@T-&,Q+3@Q
M-S,M-&4X92TY.65C+3(X8C9E,F(U.&(Y9"(@<W1%=G0Z=VAE;CTB,C Q-RTP
M,RTQ,E0Q-#HP-3HS,2TP-#HP,"(@<W1%=G0Z<V]F='=A<F5!9V5N=#TB061O
M8F4@4&AO=&]S:&]P($-#(#(P,3<@*$UA8VEN=&]S:"DB('-T179T.F-H86YG
M960](B\B+SX@/')D9CIL:2!S=$5V=#IA8W1I;VX](F-O;G9E<G1E9"(@<W1%
M=G0Z<&%R86UE=&5R<STB9G)O;2!I;6%G92]P;F<@=&\@:6UA9V4O:G!E9R(O
M/B \<F1F.FQI('-T179T.F%C=&EO;CTB9&5R:79E9"(@<W1%=G0Z<&%R86UE
M=&5R<STB8V]N=F5R=&5D(&9R;VT@:6UA9V4O<&YG('1O(&EM86=E+VIP96<B
M+SX@/')D9CIL:2!S=$5V=#IA8W1I;VX](G-A=F5D(B!S=$5V=#II;G-T86YC
M94E$/2)X;7 N:6ED.C8P8C8R-S8T+3)B,&0M-#=E,RTY8S)A+3<T939C-#DS
M8C5F-R(@<W1%=G0Z=VAE;CTB,C Q-RTP,RTQ,E0Q-#HP-3HS,2TP-#HP,"(@
M<W1%=G0Z<V]F='=A<F5!9V5N=#TB061O8F4@4&AO=&]S:&]P($-#(#(P,3<@
M*$UA8VEN=&]S:"DB('-T179T.F-H86YG960](B\B+SX@/"]R9&8Z4V5Q/B \
M+WAM<$U-.DAI<W1O<GD^(#QX;7!44&<Z36%X4&%G95-I>F4@<W1$:6TZ=STB
M-C8N,# P,# P(B!S=$1I;3IH/2(U,2XP,# P,# B('-T1&EM.G5N:70](E!I
M8V%S(B\^(#QX;7!44&<Z4&QA=&5.86UE<SX@/')D9CI397$^(#QR9&8Z;&D^
M0WEA;CPO<F1F.FQI/B \<F1F.FQI/DUA9V5N=&$\+W)D9CIL:3X@/')D9CIL
M:3Y996QL;W<\+W)D9CIL:3X@/')D9CIL:3Y";&%C:SPO<F1F.FQI/B \+W)D
M9CI397$^(#PO>&UP5%!G.E!L871E3F%M97,^(#QX;7!44&<Z4W=A=&-H1W)O
M=7!S/B \<F1F.E-E<3X@/')D9CIL:3X@/')D9CI$97-C<FEP=&EO;B!X;7!'
M.F=R;W5P3F%M93TB1&5F875L="!3=V%T8V@@1W)O=7 B('AM<$<Z9W)O=7!4
M>7!E/2(P(CX@/'AM<$<Z0V]L;W)A;G1S/B \<F1F.E-E<3X@/')D9CIL:2!X
M;7!'.G-W871C:$YA;64](E=H:71E(B!X;7!'.FUO9&4](E)'0B(@>&UP1SIT
M>7!E/2)04D]#15-3(B!X;7!'.G)E9#TB,C4U(B!X;7!'.F=R965N/2(R-34B
M('AM<$<Z8FQU93TB,C4U(B\^(#QR9&8Z;&D@>&UP1SIS=V%T8VA.86UE/2)"
M;&%C:R(@>&UP1SIM;V1E/2)21T(B('AM<$<Z='EP93TB4%)/0T534R(@>&UP
M1SIR960](C,U(B!X;7!'.F=R965N/2(S,2(@>&UP1SIB;'5E/2(S,B(O/B \
M+W)D9CI397$^(#PO>&UP1SI#;VQO<F%N=',^(#PO<F1F.D1E<V-R:7!T:6]N
M/B \+W)D9CIL:3X@/')D9CIL:3X@/')D9CI$97-C<FEP=&EO;B!X;7!'.F=R
M;W5P3F%M93TB159((%)'0B(@>&UP1SIG<F]U<%1Y<&4](C$B/B \>&UP1SI#
M;VQO<F%N=',^(#QR9&8Z4V5Q/B \<F1F.FQI('AM<$<Z<W=A=&-H3F%M93TB
M4$%.5$].12 V-C(B('AM<$<Z;6]D93TB4D="(B!X;7!'.G1Y<&4](E!23T-%
M4U,B('AM<$<Z<F5D/2(S-B(@>&UP1SIG<F5E;CTB-#4B('AM<$<Z8FQU93TB
M,3 U(B\^(#QR9&8Z;&D@>&UP1SIS=V%T8VA.86UE/2)004Y43TY%(#,Q,34@
M0R(@>&UP1SIM;V1E/2)21T(B('AM<$<Z='EP93TB4%)/0T534R(@>&UP1SIR
M960](C,U(B!X;7!'.F=R965N/2(Q.#DB('AM<$<Z8FQU93TB,3DU(B\^(#QR
M9&8Z;&D@>&UP1SIS=V%T8VA.86UE/2)004Y43TY%(#$U."!#(B!X;7!'.FUO
M9&4](E)'0B(@>&UP1SIT>7!E/2)04D]#15-3(B!X;7!'.G)E9#TB,C0S(B!X
M;7!'.F=R965N/2(Q,3$B('AM<$<Z8FQU93TB,S<B+SX@/')D9CIL:2!X;7!'
M.G-W871C:$YA;64](E!!3E1/3D4@,S0P($,B('AM<$<Z;6]D93TB4D="(B!X
M;7!'.G1Y<&4](E!23T-%4U,B('AM<$<Z<F5D/2(P(B!X;7!'.F=R965N/2(Q
M-#@B('AM<$<Z8FQU93TB.30B+SX@/')D9CIL:2!X;7!'.G-W871C:$YA;64]
M(E!!3E1/3D4@0V]O;"!'<F%Y(#$Q($,B('AM<$<Z;6]D93TB4D="(B!X;7!'
M.G1Y<&4](E!23T-%4U,B('AM<$<Z<F5D/2(X-2(@>&UP1SIG<F5E;CTB.#8B
M('AM<$<Z8FQU93TB.3 B+SX@/')D9CIL:2!X;7!'.G-W871C:$YA;64](E!!
M3E1/3D4@,3DS-2!#(&-O<'DB('AM<$<Z;6]D93TB4D="(B!X;7!'.G1Y<&4]
M(E!23T-%4U,B('AM<$<Z<F5D/2(R,#,B('AM<$<Z9W)E96X](C B('AM<$<Z
M8FQU93TB-C$B+SX@/')D9CIL:2!X;7!'.G-W871C:$YA;64](E!!3E1/3D4@
M,3$V($,@(B!X;7!'.FUO9&4](E)'0B(@>&UP1SIT>7!E/2)04D]#15-3(B!X
M;7!'.G)E9#TB,C4U(B!X;7!'.F=R965N/2(R,#8B('AM<$<Z8FQU93TB,"(O
M/B \<F1F.FQI('AM<$<Z<W=A=&-H3F%M93TB4$%.5$].12 S.# @0R!C;W!Y
M(B!X;7!'.FUO9&4](E)'0B(@>&UP1SIT>7!E/2)04D]#15-3(B!X;7!'.G)E
M9#TB,C$Y(B!X;7!'.F=R965N/2(R,C@B('AM<$<Z8FQU93TB-C@B+SX@/"]R
M9&8Z4V5Q/B \+WAM<$<Z0V]L;W)A;G1S/B \+W)D9CI$97-C<FEP=&EO;CX@
M/"]R9&8Z;&D^(#PO<F1F.E-E<3X@/"]X;7!44&<Z4W=A=&-H1W)O=7!S/B \
M+W)D9CI$97-C<FEP=&EO;CX@/"]R9&8Z4D1&/B \+W@Z>&UP;65T83X@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" \/WAP86-K970@96YD/2)W(C\^_^(,6$E#
M0U]04D]&24Q%  $!   ,2$QI;F\"$   ;6YT<E)'0B!865H@!\X  @ )  8
M,0  86-S<$U31E0     245#('-21T(               $  /;6  $
MTRU(4" @
M           18W!R=    5     S9&5S8P   80   !L=W1P=    ?     4
M8FMP=    @0    4<EA96@   A@    49UA96@   BP    48EA96@   D
M   49&UN9    E0   !P9&UD9    L0   "(=G5E9    TP   "&=FEE=P
M ]0    D;'5M:0   _@    4;65A<P  ! P    D=&5C:   !#     ,<E12
M0P  !#P   @,9U120P  !#P   @,8E120P  !#P   @,=&5X=     !#;W!Y
M<FEG:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($-O;7!A;GD  &1E<V,
M        $G-21T(@245#-C$Y-C8M,BXQ               2<U)'0B!)14,V
M,3DV-BTR+C$
M                 %A96B        #S40 !     1;,6%E:(
M          !865H@        ;Z(  #CU   #D%A96B        !BF0  MX4
M !C:6%E:(        "2@   /A   ML]D97-C         !9)14,@:'1T<#HO
M+W=W=RYI96,N8V@              !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M
M9&5S8P         N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@
M<W!A8V4@+2!S4D="               N245#(#8Q.38V+3(N,2!$969A=6QT
M(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M &1E<V,         +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)
M14,V,3DV-BTR+C$              "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD
M:71I;VX@:6X@245#-C$Y-C8M,BXQ
M  !V:65W       3I/X %%\N !#/%  #[<P !!,+  -<G@    %865H@
M  !,"58 4    %<?YVUE87,          0                        */
M     G-I9R      0U)4(&-U<G8        $      4 "@ / !0 &0 > ",
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MA!5U4T2T8/&C)18W".+CI&2%M287_]H # ,! 0(1 Q$   "?P
M           69Z.''*WPQP!>G1R[&FAV2
M!_/K>):\=OA.ILEYSKI,V3B#W6]2^[^?3^_5(<;JR#T>AYH\?KVR4=[QMW%7
MWEOR@                            69Z.''*WPQP!>G1R[&FAV2
M           !#ISO6_+O;U@2^L%V/VV/[0      *;X..$.F'@PMT2_;<Q+*
M5^%EZ]&2EE9&@L /HQJWB=NWK=Y1L+B6C9!H=807IN.9CW_6K+6PC&FR&W;N
MVWR;SG.@                           69Z.''*WPQP!>G1R[&FAV2
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M^YA07H]3\78           !97HXX93_EMCN_,EHCNR3B>\  "S/1PXY6^&.
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M3ZO7"N]?Z!QE]^,:@"8%@NQP_<Z5P  ;):G[>H7IY>[X\W*#)L958F6;*^
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M@  >,S>-X5VT7\]N,WS$V1K<7)UR,D:_$2]P1DK'&^UGTEZS&FN3O>XSN
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MW1?[@@#\'-<VTI.CW(D6 ,[*YZLF8?OPQL'FQ(F_.!('QC+]$_5BY5+A^@"
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M=L!%7=78R[*_&>0;2ZF91?TK_%F2U@?;D
M                      #1YG+YLQ_<^_-FTN<UXAKG;/-]9_?4H[LK$7(5
M:,]FU^5V4E_Y4^G_ -?[V     8M3/1RX=QJ'BU,]&^+X;_37<?\C=V[NKL9
M=E?C+KKD=A']._G7)5^SFG^?-/R*
M                 !X1/8RA<[G_  &LKME*!UVGQ+5R5M3 7"I1W96(N0JT
M9[-XMAV^E,Y(^BOU_O8   !CI*]/-)VVI&MBV^(2SOY7_M3FCJ'E2[*_&777
M(ZZ:M&86_P!"7R0F-;?>+_0                       "D<_S6-</#M0IG
MO 'F/LX8@3OFV&U;V8F3?GQ+G/. ![Y&=N==;]8 U=7'P940WHR=A^\ 856#
MS>G^/GD-%]P'@DGU8)V3R  #/>L^OY.3P^1Z<ZZWZP!B9-^?Z_S]RHA>\  1
M<]H?COJ9RCJK0.%IH/5:O+,#]5LZQ1M1A^=8BY"K1GLVNRNR<KS)?TC]0]5A
M   U=W'P<[/::FX3V'S#(3 N2IC/\C_VRNZNQMUUR.NFK1E8BH#VC^NWXW;R
M?/=                        !XQ(=?)DW9Q[V M%LC #4Q=X^$QL'5^F=
MJ+>(9>?*U'+RK"[ *S[ !N$HDC+DP?8@/*?;U\E7=O'N_G&<OT!]8[> (&.R
ME3VSTB0DSXBG -/=[CHC><*Z-?\ 9O'4./[GA6_6)@^";'A98?-'_P FP_0T
MU<N( AEY\K5Y]'*8#@JQ@ #&*S8BA?[C_#:R^4[0>NU6EWR%D57]I&KD;4\,
M1E8BI"K1GL]YZ+K(]O.^.Y>Z;35SL]8&-TOYH?\ G.NQ2,TP-O\ ;^ 2(?@/
M])=U7Q[W%NNN1UTU:,NNJ1OF7U TXDJ_;_5BK=?8
M    /&)#KY,F[./>P%HMD8 :F+O'PF-@ZOTSM1;Q#+SY6A,TP'90  !$FS=7
ML.I[S1_,G1'3VT_O.5<+Z (&.RE3VSTB0DSXBG  !#+SY6KSZ.4P'!5C CEY
M6AH_^38?H::N7$ 0R\^5J\^CE,!P58P  (_N>_G/'PSIH=0>NU6EWR%F>CUV
MFG:34I/^^$O!7L3>"Y<>^.XZKV>S]M\V=Y5VP])S5GW2ADWQZ#,E^'S;E.?S
M_.T#)C7/)\QW^2/['^@TCJNFK1EUU2-^SG4]F_\ 5E\T,V\C>
M              #QB0Z^3)NSCWL!:+9& &IB[Q\)C8.K],[46\0R\^5H3-,!
MV4  "B=GYRE]T:!TSM1;Q&=R[!^6^SKFTZ]V@"!CLI4]L](D),^(IP  0R\^
M5J\^CE,!P58P(Y>5H:/_ )-A^AIJY<0!#+SY6KSZ.4P'!5C   ^#L\\0W:OY
M%:T;YAVTN^0LST>NTT[;_P"66V^-FM7G/6SPL5LIZR^[VVDFK:Y66VN-GM?]
MG*'U6#^?YVBO0GOEW?RG?7?.K2S*=TU:,NNJ1MU5*)R[_H!T8V<_2?"0
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M9VHMXAEY\K4?_)T1LSJ'N &T"G^[=SCR4YRVU=,ZL>EU^^[C^@#2%D.+A5[
MUCJ(Z=WN!CLI4]8UO\&:=?\ 4 )UNN%KR'B^Z&7GRM7GT<I@."K&!'+RM#1_
M\FP_0TU<N( AEY\K5Y]'*8#@JQ@     #'2E9.U/ZS;C:Z,19/Q/QW8JS2?=
M[#ABZ>@TK\NZNQEUUZ-]/]-6RNV'PKF-N;@/+W?S ->M<6
M              /&)#KY,F[./>P%HMD8 :F+O'PF-@ZOTSM1;Q#+SY6H9>?*
MT !( QE+[FZ#)8(V3RSN];K6 !\7+\XWV^6-^N=H_D.%CL!68LN9($ #K-Z3
M9!S-@/3#+SY6KSZ.4P'!5C CEY6AH_\ DV'Z&FKEQ $,O/E:O/HY3 <%6,
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M,(\@$K6[[J$$,\%I'0(J)NMWTF1%R1:-<]6N+6[J/ZP;.B80&5%$J6")EM'
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M(M0C^K&KI.<J9.Y:FX'#%E@95.+6]1J="+Q6W-UE'GK<L*D5D05\UJ:\KHR
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M)30$,DW4N-UMWT&[B&C4&C4&3,&S<I2V@V@(Y<FGZKR6G5_Y*V%BI!7@JZ1
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MSH?ZZ0<3BL[\6WB^$N"Q\7N\UQ-%PBME<+C@F0:O%. X=+$;SP+NVS;H;\#
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MP6/B]WFO\%Y>QKE_KNC]0S#/[[->:(>1_P #_]H " $#  $% /PT3P:A^/\
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MT).%TY.BC@*(IDQ(-")4RJ1"$Y&$"NF0@=85>I W43,4U2JI@3P:A^/086D
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MF+*P[4H41C0Q,Y!4U^:"QF"QF"IJ"YCE  \JH+F/RS*FH)G.4$SD #\X '@
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MJ)9(0@?(JI'L<J,K;'896;W.-RN[>Y1?+3"&U@EL<9R9."9."9."9.%ZT_\
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MC]IC:>S5DUUM[B2+6I36ZMV6M,Z5I6E33^07.U-L7\-KLZ%=9Y975$4<99B
M.3C.0SQ/L[[N-E?ZA>"H^E7 >.V!XTB&K-,.5C".$:XP[=K>TUS<VI-1 #U=
MNM#4:L$>K%494<J7-!K,3G@D#!RP<L&P^[/L#M':[JVJ\D,>K;Q,14":[D*6
ML!(T==,E>#%O>_>E]X.SMB6YH3;V<;7]S3*J.Y:WMXV.?2C>Y49&C5($3;>L
M-L]H+@9GZ9?/$A:G FSULB%!S"L[\3%QIC79GW&]FF* 4:XL8;MQ2E")+M9W
MUAJ@ZVMK5J:U)KU%E]VVP(8:UU4V?:(M3I-%A KEGA$O_NS[/SHIJ!)LZS<
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M.F0;C6ARU37N]CM^!*)<KU<E/^(@Z)/*R9?W>YMO[0GO.X[*^Q_K'W]ILVU
MZZ5Z5.A1I9FXE506;D!Q<)LJ2O9?9RFULAP-&C'7N#P%[F4M,30'4:-#D@P2
M!N$@8) Q-]XNU+:G:/M H,51G%8(U8@.$&Y<&=B#1XQ;Y!E-=UG=@$ J2<@
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M_6159!SQGI@>Q9SZW$5Y8W*2VKBJLI!![XX1H(T@Y$5WEUL]E'TL#7A8^ED
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M0:P2^NU65ETI E9+B0<%4A1V%<B0!PXM-G6,"Q65O$L<:***D:*%1%' JJ
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MXC&Q4 \ZA3S$;^P_V]/TT^]V$Q&EI![J&1?/[^C<M-LHGP-[;C6/]I#1&_\
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M1- P&AE/I7&=#H.@@BE(]H;+N1)"=(T,A]2ZZ58<7#I!((/<7EE<+&HJ230
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M''PD>?OXKNRN'BNHS564T(/./-&@C(Y8CM.U$)5\AU\8J#RR1C,'C* @\"#
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M *M? 2YX:M0^3C9:2O1Y>TMFBY'-A;7STR&711C4T&5-) )SP<\L$ X.>/N
M@,K+3M?LIZJ:'X.\ADU>9M758<*DC%W%6C7$L<8]UUA\R,UY.XBXL;N2&<:&
M1F1O"I!P%>^2X0<$J!OREU'/?8X'TG8ENY]:SIX]?'\.Q_/']GBEKLVTCY2'
M<][IJ/"#ADN=LR)"?2Q4B%.+H!6(]D3@DFI/<9;78^T3# [ZS#4C<%J 5Z:-
M3( 94K08_?G_ (-O^RQ^_/\ P;?]EC]^?^#;_LL7%_>S&2[E<L[&@J3IR
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MQ_$4?S)_:8_B*/YD_M,;/VP^VDE6!B=41%2:JRZ=<TTUT8VY_<_]1%N=I_\
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MAK6S)*EPPH5FN&#10$$%0LTP.M"H:.*)0L2@  9  "@ '  ,J8 )P,\L#/+
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M:*M !HP,\#/ SP,\; @U:,MG%7@Z112W%Z8GEX\\*B"KDT PL8S<YL>,^@-
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M=Y;^S7QC>7*\4C>,[Q;:Y- NAM(IQ'SL5^E)X<'JR7;D%!X33S*XDF= M'(
M'%0'OG/DWOWD?_M__P#*6.%Q:2$](QBO.!0^;7'+@ G SQR8BM]8FZLKF2!Z
MT\GXV,CUNK+J@Y9H>*I_D)V)++6XV-M*>W X1%+JW2'F+3RJO%J4R%,'/!SP
M<\\$DX^YO[T(( +BSVC=;+F<:62[A%U;JW)&UG<E:4SF:M<J;.^7C]^-]K(/
M@'.7(>+T.3F.]I'<N!Q5J/ :XI])/@7T,4EG9EXJY>#1O!%+5K<^%>4<G)X.
M4$:#O4N%'1<9\X]$4\W?11D=,BIYSZ&CO;UX9-!\P\![V'AE'2'FCC'(>Z=?
M*/AV&CU(XN<\/@W7YCO$YQO#=Q+\&WE<AX^8^/GWM(IV4<5<O!HQ3Z2:<R^.
MF*/<N1ST'@%-YETH3I7SQQ'QX26.NHPJ*Y=SN_DF]Z=Y;^S7QC>7 ID37PBO
MCKOY?E3[U=[]Y<*L01#:29"N46T+24BF6D)0G@&>=*87#P$]*-LN9L_'7 !.
M>.7 !.!GC;O9>:2D=_;"6,$_UMN34*.-HI'8\8C%='\B^]C83R5CFBL[F,99
M=4T\+D</2$L5=(&J-%<R <'//!)." <?>'<Z@:ZV7=;.O(P0-*WT%O(021JD
M07,QJ*D@% "6QL&UU6(EO8$H-)UI5%!RYY9:=\\,JU0_SJ.7'2SB.AO./$?Y
MCN2W-TO2TJIX.4\O$.#AWTJ@=->D.]Z(J-[$A'0!UCS#T30=_?A6RD&@\7/Q
MC!BF6C>8>4<8[B HJ3A;BZ7X3@7BY3R\G!SZ-U^8[Q.<;QD<54BA&#+$"UL?
M"O(>3B/AY>XK/<*1!P#U7XO'P8  R[G=_)-[T[RW]FOC&\CNU&CHMS<!\.7?
M&_E^5/O5WOWJ;/1:R'85XZC15H87F4<&EHP,\N/*N%PBL?@Y.B>_2A\/F$[@
M!.>.7 !.-@]IK6IDL[E7*C+72M)$_O(RR'D;%GM*QF$EE<1))&PT,CJ&5AR%
M2#_()"#TVZ([^GP"N.T-J7(2?L]. . NEU9,">*BZ_AYL'//!)." <$DYX^_
M2WF9@H[.7;BE*UB3K5&8.19 &Y*@$',=A+8+53M6V=AQK'*LCC2/2H>&HX*F
M@.^9)%!0Z0<%[-LO4GSCZ/AQJ2QE6Y13?#JHCJ\9R'AX>]4X$DG3GX^ <P\\
M^9W":(#H5J.8YCP:.]O)+AATG-!S#T3XNX&.9 5\T<QX,%K8Z\?%Z8><>]X,
M%74AAP'([X$1ZL?&V7@&D^+EP& UIO5'SAP>/EWK\QWB<XWI!&6#):$*_J3H
M[W%XN;&K/$5\7>.@[[5AB+<O .<Z,+)<D/)Q>E'H^+D[K=_)-[T[RW]FOC&\
M9'6J$4(PTD*EK?PD<_H^&F]"1(6?B&#'-0.7)H,Z9 9\N6]OMFW0)M;B%XGH
M:'4D4HU#P&A-#C:6QKU:7EI<R0R#11XG9&%.1E. 1I_[L(Y/P@R;GX^_IW "
M<\<N.7%QV'OYO_--F5>&IS>U=M X289&*G@"/$H\DT[N8T/P4>7.>$^=WL;1
MD1:K'L&Y9M&0,]HM>7I,HRXZZ <$DX.>"2<\5.G'WZ,(U<MV4VFE#F/A+26.
MO.NMK+ZX XV9<LE4L;:XG.66<9@4GF:92.4#N.K(@9>(BOCQ41E3ZT^<:CS,
M="X<<X!]#'UH^Y_'CIRN? /.. 4MP6XSGX_.[DKSQ:S 4TD9=XC'U?\ *;^E
MCZO^4W]+'U?\IOZ6$CC6B** =RU9HE8<HK@ZJLG,?1KCHW+ <P/H8SN6IS#T
M<5=W;O@#S!7S< Q0*&X])\)J=^0=&/JJ> 8^JIX!CZJG@&*BU2O,-^5905/'
M@DP:I];EYFCS,="=QST/G#'UH^Y_'CISN>:@\XX!$.LWKL_,T>9@*H  WWU5
M/ ,?54\ Q]53P#'U5/ -ZR,*J10CD./JJ> 8^JIX!CZJG@& RVR!@>+?$R6X
MUN,9'S*5[^.B\@[X\\8Z4TGF>@<5,18\I/G4&-6*,*O$!3?]O(5B*VFT+A;^
M,Z-87B"65AS7)G7G7O8&-/0;(^CWMT G/'+C9/:;9+_XNVD!*DT61#E)$_K9
M$)4G2*AA1@"-E]I=BS:^S[J(,/5*VAXW' \;@HXX&4T)%#W;50_#OD.3C/H<
MO-N=MML:N4&R%AKGEU]Q&].+/Z/PBN65,ZG/!).>*G3@YX^]ZX+T,MA%;Z3_
M ,U=V]M3+/,2Y\%*ZW1KCM7VEDCS=X[:,^Q!EE'+76AT<7+E_P!I>POWCVT1
M)B9]GW! KT7UKBV)XE5A<@DY:TB"H) (QW\ '@W0"<\<N&V-MN9CV/OG'6:3
M]'ER5;A1ZDBBS*,R@5Q4QA6BN+>59+>10RLI#*RL*JRL*@@@@@@T(S'=&FE/
M1'FGB&'FD/2/F#@ W.W':1DH;W:$5N#QK:Q%ZCDUKHCE((X,$DYXJ=.#G@YY
MXV3V<1_\1M?;<"E:TK#;1RSNW+JRK;BFCI5X #L+9[QZMU)&9Y>/7F.O0\J*
M53VG_:;M;V,95^E7=J3 33HW,1$MNU32@ZY$#FHJA8$T)Q+;7,31W$;LK*P(
M964T96!S!!!!!S!RQW\#'6IFO#R?B\6Z 3GCEQ;=B^VER6[,,:03FI-H2?(?
M23;DGE,1-1\'4)%<6\JR6\BAE92&5E855E85!!!!!!H1F.Y&69J*/-Y!RXUV
MRC'DCB'HGA.[V+V5-%J7TEK])F!\KK+IC/1O7(KK&1P:E-.>*G!P<\\'/+'W
M?_=O$W6;,V'8FXNAP*]TRRR(P]=;PVH#9YSC+36@T?A(L3D,!1<"I/$?0WK2
M2-1!I.%BBG!D.@9\ KQ<6XG7RA=:M-/!IT<^/K(\!]#'UD> ^ACZR/ ?0Q]9
M'@/H8^LCP'T,=7#,&>E:9^AO3%+(0XY"=/-CK86JE:<6>]"3RA6(KP^<,%X'
MUD!IW^_S[SK)GU4K2N/K(\!]#'UD> ^ACZR/ ?0Q]9'@/H8^LCP'T,?61X#Z
M&.LA?63CQUDSZJ5I7'5PS!GI6F?H;U.OE"ZU::>#3HY\,8) P&G3Y^_;M9LV
MWU>S_:'7GR'12\4CZ4G)UA9;@$GI-+(%%(SCOX&!@R6^3<7!WO0P58$,.#<
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M8Q;^V]ZVY9^W_-Q)U*J=:E:@\%>(CCQ\5%X&_I8^*B\#?TL?%1>!OZ6/BHO
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MVQ&BQF&R-QPR$  5551$VRWI>Z&\RFXKHK".3CVH6NN-R'H&4ZMNAXQ%MZ+
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M)LG#9.&Y$\*[#PW;MWH>#ZZ_7VDQ$3<9M*3!+PY9 )S,DJ_X*N(B%]455-B
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M;A*J(L92%B%9UDV)8UMC$CSZ^P@2&9D&?!F,A(B384N.;D>5$E1W!-MP"(#
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M6>F0TD.785&F4:*_!TBI428W(!(LZBERLA;(4!SER'LW$WM(B?B'AG]5Z/\
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M6L[E&-":0.T/E$%?DO$I/RY)B*<SKI&X>[B2_NSKS_8QJC^0]YMH/_;-I?\
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:^T3^B_T6/_0OZ%_-!_1/^R_^;_Q-W]P__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140693377778768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover Page Cover Page<br></strong></div></th>
<th class="th"><div>May 03, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Class A Common Stock of Evolent Health, Inc., par value $0.01 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Evolent Health, Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">571<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">389-6000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37415<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">32-0454912<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">800 N. Glebe Road<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Arlington<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">VA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">22203<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">EVH<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May  03,  2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001628908<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>evh-20230503_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="evh-20230503.xsd" xlink:type="simple"/>
    <context id="id598b4ef6927435d9f551b05ce16b3bb_D20230503-20230503">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
        </entity>
        <period>
            <startDate>2023-05-03</startDate>
            <endDate>2023-05-03</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="id598b4ef6927435d9f551b05ce16b3bb_D20230503-20230503"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NGIxMTJjYTU3YjQyMDU5YjYwYTlhOWY0ZmY4YTA0L3NlYzo0NDRiMTEyY2E1N2I0MjA1OWI2MGE5YTlmNGZmOGEwNF80L2ZyYWc6YzE5MjBlN2FhMmYzNDkyYTgxMWJhYjY5MGY1OGMzMWQvdGFibGU6MzA0MDQ2ZWFhODNkNGRmN2JlZTRiMTRmZDkzODhiMGMvdGFibGVyYW5nZTozMDQwNDZlYWE4M2Q0ZGY3YmVlNGIxNGZkOTM4OGIwY18zLTEtMS0xLTEwMTQxNw_0226155c-8bd0-400b-bad2-11aea14923d0">0001628908</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="id598b4ef6927435d9f551b05ce16b3bb_D20230503-20230503"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NGIxMTJjYTU3YjQyMDU5YjYwYTlhOWY0ZmY4YTA0L3NlYzo0NDRiMTEyY2E1N2I0MjA1OWI2MGE5YTlmNGZmOGEwNF80L2ZyYWc6YzE5MjBlN2FhMmYzNDkyYTgxMWJhYjY5MGY1OGMzMWQvdGFibGU6MzA0MDQ2ZWFhODNkNGRmN2JlZTRiMTRmZDkzODhiMGMvdGFibGVyYW5nZTozMDQwNDZlYWE4M2Q0ZGY3YmVlNGIxNGZkOTM4OGIwY182LTEtMS0xLTEwMTQxNw_191a14b3-1ef7-4703-9820-a3c078eac4a3">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="id598b4ef6927435d9f551b05ce16b3bb_D20230503-20230503"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NGIxMTJjYTU3YjQyMDU5YjYwYTlhOWY0ZmY4YTA0L3NlYzo0NDRiMTEyY2E1N2I0MjA1OWI2MGE5YTlmNGZmOGEwNF8xL2ZyYWc6ZTkxNDZhZGU1OWMwNDNmZThhYjIzZTEyNzQ4YjI2MjYvdGV4dHJlZ2lvbjplOTE0NmFkZTU5YzA0M2ZlOGFiMjNlMTI3NDhiMjYyNl8xNjYx_30efb3f0-297e-47bc-b24c-1bb725c6766b">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="id598b4ef6927435d9f551b05ce16b3bb_D20230503-20230503"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NGIxMTJjYTU3YjQyMDU5YjYwYTlhOWY0ZmY4YTA0L3NlYzo0NDRiMTEyY2E1N2I0MjA1OWI2MGE5YTlmNGZmOGEwNF8xL2ZyYWc6ZTkxNDZhZGU1OWMwNDNmZThhYjIzZTEyNzQ4YjI2MjYvdGV4dHJlZ2lvbjplOTE0NmFkZTU5YzA0M2ZlOGFiMjNlMTI3NDhiMjYyNl8xNTc_14be21b8-ae48-4e91-afc5-15d28abed17f">2023-05-03</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="id598b4ef6927435d9f551b05ce16b3bb_D20230503-20230503"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NGIxMTJjYTU3YjQyMDU5YjYwYTlhOWY0ZmY4YTA0L3NlYzo0NDRiMTEyY2E1N2I0MjA1OWI2MGE5YTlmNGZmOGEwNF8xL2ZyYWc6ZTkxNDZhZGU1OWMwNDNmZThhYjIzZTEyNzQ4YjI2MjYvdGV4dHJlZ2lvbjplOTE0NmFkZTU5YzA0M2ZlOGFiMjNlMTI3NDhiMjYyNl8xNjYy_2f9d3425-9ee2-4632-9bec-c25d3080ef07">Evolent Health, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="id598b4ef6927435d9f551b05ce16b3bb_D20230503-20230503"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NGIxMTJjYTU3YjQyMDU5YjYwYTlhOWY0ZmY4YTA0L3NlYzo0NDRiMTEyY2E1N2I0MjA1OWI2MGE5YTlmNGZmOGEwNF8xL2ZyYWc6ZTkxNDZhZGU1OWMwNDNmZThhYjIzZTEyNzQ4YjI2MjYvdGFibGU6NmNiNGY4NzAwOGE0NDI1MjlhNGI0Mjg5ODcwY2YxZmEvdGFibGVyYW5nZTo2Y2I0Zjg3MDA4YTQ0MjUyOWE0YjQyODk4NzBjZjFmYV8wLTAtMS0xLTEwMTQxNw_21e1c84c-2cee-445a-9f12-b91e9fe249a8">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="id598b4ef6927435d9f551b05ce16b3bb_D20230503-20230503"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NGIxMTJjYTU3YjQyMDU5YjYwYTlhOWY0ZmY4YTA0L3NlYzo0NDRiMTEyY2E1N2I0MjA1OWI2MGE5YTlmNGZmOGEwNF8xL2ZyYWc6ZTkxNDZhZGU1OWMwNDNmZThhYjIzZTEyNzQ4YjI2MjYvdGFibGU6NmNiNGY4NzAwOGE0NDI1MjlhNGI0Mjg5ODcwY2YxZmEvdGFibGVyYW5nZTo2Y2I0Zjg3MDA4YTQ0MjUyOWE0YjQyODk4NzBjZjFmYV8wLTItMS0xLTEwMTQxNw_b5b3d7f6-861c-45e4-bb87-0061b27f95a6">001-37415</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="id598b4ef6927435d9f551b05ce16b3bb_D20230503-20230503"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NGIxMTJjYTU3YjQyMDU5YjYwYTlhOWY0ZmY4YTA0L3NlYzo0NDRiMTEyY2E1N2I0MjA1OWI2MGE5YTlmNGZmOGEwNF8xL2ZyYWc6ZTkxNDZhZGU1OWMwNDNmZThhYjIzZTEyNzQ4YjI2MjYvdGFibGU6NmNiNGY4NzAwOGE0NDI1MjlhNGI0Mjg5ODcwY2YxZmEvdGFibGVyYW5nZTo2Y2I0Zjg3MDA4YTQ0MjUyOWE0YjQyODk4NzBjZjFmYV8wLTgtMS0xLTEwMTQxNw_138e9b8a-b677-4ce3-9e29-44940f1a1fb5">32-0454912</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="id598b4ef6927435d9f551b05ce16b3bb_D20230503-20230503"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NGIxMTJjYTU3YjQyMDU5YjYwYTlhOWY0ZmY4YTA0L3NlYzo0NDRiMTEyY2E1N2I0MjA1OWI2MGE5YTlmNGZmOGEwNF8xL2ZyYWc6ZTkxNDZhZGU1OWMwNDNmZThhYjIzZTEyNzQ4YjI2MjYvdGFibGU6NmNiNGY4NzAwOGE0NDI1MjlhNGI0Mjg5ODcwY2YxZmEvdGFibGVyYW5nZTo2Y2I0Zjg3MDA4YTQ0MjUyOWE0YjQyODk4NzBjZjFmYV8zLTAtMS0xLTEwMTQxNw_64ee7677-2840-423c-a503-1f3932dcbfa3">800 N. Glebe Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="id598b4ef6927435d9f551b05ce16b3bb_D20230503-20230503"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NGIxMTJjYTU3YjQyMDU5YjYwYTlhOWY0ZmY4YTA0L3NlYzo0NDRiMTEyY2E1N2I0MjA1OWI2MGE5YTlmNGZmOGEwNF8xL2ZyYWc6ZTkxNDZhZGU1OWMwNDNmZThhYjIzZTEyNzQ4YjI2MjYvdGFibGU6NmNiNGY4NzAwOGE0NDI1MjlhNGI0Mjg5ODcwY2YxZmEvdGFibGVyYW5nZTo2Y2I0Zjg3MDA4YTQ0MjUyOWE0YjQyODk4NzBjZjFmYV8zLTItMS0xLTEwMTQxNw_76a3d79f-e023-48e6-a460-d0ed396754e1">Suite 500</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="id598b4ef6927435d9f551b05ce16b3bb_D20230503-20230503"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NGIxMTJjYTU3YjQyMDU5YjYwYTlhOWY0ZmY4YTA0L3NlYzo0NDRiMTEyY2E1N2I0MjA1OWI2MGE5YTlmNGZmOGEwNF8xL2ZyYWc6ZTkxNDZhZGU1OWMwNDNmZThhYjIzZTEyNzQ4YjI2MjYvdGFibGU6NmNiNGY4NzAwOGE0NDI1MjlhNGI0Mjg5ODcwY2YxZmEvdGFibGVyYW5nZTo2Y2I0Zjg3MDA4YTQ0MjUyOWE0YjQyODk4NzBjZjFmYV8zLTQtMS0xLTEwMTQxNw_453d1be8-32cb-42ad-87d4-e98917061360">Arlington</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="id598b4ef6927435d9f551b05ce16b3bb_D20230503-20230503"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NGIxMTJjYTU3YjQyMDU5YjYwYTlhOWY0ZmY4YTA0L3NlYzo0NDRiMTEyY2E1N2I0MjA1OWI2MGE5YTlmNGZmOGEwNF8xL2ZyYWc6ZTkxNDZhZGU1OWMwNDNmZThhYjIzZTEyNzQ4YjI2MjYvdGFibGU6NmNiNGY4NzAwOGE0NDI1MjlhNGI0Mjg5ODcwY2YxZmEvdGFibGVyYW5nZTo2Y2I0Zjg3MDA4YTQ0MjUyOWE0YjQyODk4NzBjZjFmYV8zLTYtMS0xLTEwMTQxNw_2cdb5849-7875-4bbe-b88e-6435542c206e">VA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="id598b4ef6927435d9f551b05ce16b3bb_D20230503-20230503"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NGIxMTJjYTU3YjQyMDU5YjYwYTlhOWY0ZmY4YTA0L3NlYzo0NDRiMTEyY2E1N2I0MjA1OWI2MGE5YTlmNGZmOGEwNF8xL2ZyYWc6ZTkxNDZhZGU1OWMwNDNmZThhYjIzZTEyNzQ4YjI2MjYvdGFibGU6NmNiNGY4NzAwOGE0NDI1MjlhNGI0Mjg5ODcwY2YxZmEvdGFibGVyYW5nZTo2Y2I0Zjg3MDA4YTQ0MjUyOWE0YjQyODk4NzBjZjFmYV8zLTgtMS0xLTEwMTQxNw_9543ea6a-ea0a-4b3f-a8dc-4b00055673aa">22203</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="id598b4ef6927435d9f551b05ce16b3bb_D20230503-20230503"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NGIxMTJjYTU3YjQyMDU5YjYwYTlhOWY0ZmY4YTA0L3NlYzo0NDRiMTEyY2E1N2I0MjA1OWI2MGE5YTlmNGZmOGEwNF8xL2ZyYWc6ZTkxNDZhZGU1OWMwNDNmZThhYjIzZTEyNzQ4YjI2MjYvdGV4dHJlZ2lvbjplOTE0NmFkZTU5YzA0M2ZlOGFiMjNlMTI3NDhiMjYyNl8xNjYz_cfa25127-2ea1-4599-a951-e4561f65e82c">571</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="id598b4ef6927435d9f551b05ce16b3bb_D20230503-20230503"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NGIxMTJjYTU3YjQyMDU5YjYwYTlhOWY0ZmY4YTA0L3NlYzo0NDRiMTEyY2E1N2I0MjA1OWI2MGE5YTlmNGZmOGEwNF8xL2ZyYWc6ZTkxNDZhZGU1OWMwNDNmZThhYjIzZTEyNzQ4YjI2MjYvdGV4dHJlZ2lvbjplOTE0NmFkZTU5YzA0M2ZlOGFiMjNlMTI3NDhiMjYyNl8xNjU3_c8eb53ce-42ae-44b6-8428-1c3275fd6edf">389-6000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="id598b4ef6927435d9f551b05ce16b3bb_D20230503-20230503"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NGIxMTJjYTU3YjQyMDU5YjYwYTlhOWY0ZmY4YTA0L3NlYzo0NDRiMTEyY2E1N2I0MjA1OWI2MGE5YTlmNGZmOGEwNF8xL2ZyYWc6ZTkxNDZhZGU1OWMwNDNmZThhYjIzZTEyNzQ4YjI2MjYvdGV4dHJlZ2lvbjplOTE0NmFkZTU5YzA0M2ZlOGFiMjNlMTI3NDhiMjYyNl8xNjU4_fb336948-ce58-46b9-a41b-aa94c53bfe61">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="id598b4ef6927435d9f551b05ce16b3bb_D20230503-20230503"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NGIxMTJjYTU3YjQyMDU5YjYwYTlhOWY0ZmY4YTA0L3NlYzo0NDRiMTEyY2E1N2I0MjA1OWI2MGE5YTlmNGZmOGEwNF8xL2ZyYWc6ZTkxNDZhZGU1OWMwNDNmZThhYjIzZTEyNzQ4YjI2MjYvdGV4dHJlZ2lvbjplOTE0NmFkZTU5YzA0M2ZlOGFiMjNlMTI3NDhiMjYyNl8xNjY0_2baf53eb-66a4-4db4-b826-b1388c9c97ce">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="id598b4ef6927435d9f551b05ce16b3bb_D20230503-20230503"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NGIxMTJjYTU3YjQyMDU5YjYwYTlhOWY0ZmY4YTA0L3NlYzo0NDRiMTEyY2E1N2I0MjA1OWI2MGE5YTlmNGZmOGEwNF8xL2ZyYWc6ZTkxNDZhZGU1OWMwNDNmZThhYjIzZTEyNzQ4YjI2MjYvdGV4dHJlZ2lvbjplOTE0NmFkZTU5YzA0M2ZlOGFiMjNlMTI3NDhiMjYyNl8xNjU5_ec94b152-9617-4225-acc3-b138fd44d54a">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="id598b4ef6927435d9f551b05ce16b3bb_D20230503-20230503"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NGIxMTJjYTU3YjQyMDU5YjYwYTlhOWY0ZmY4YTA0L3NlYzo0NDRiMTEyY2E1N2I0MjA1OWI2MGE5YTlmNGZmOGEwNF8xL2ZyYWc6ZTkxNDZhZGU1OWMwNDNmZThhYjIzZTEyNzQ4YjI2MjYvdGV4dHJlZ2lvbjplOTE0NmFkZTU5YzA0M2ZlOGFiMjNlMTI3NDhiMjYyNl8xNjY1_6f1c2135-fc09-4b9b-a92b-4405d90f06e1">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="id598b4ef6927435d9f551b05ce16b3bb_D20230503-20230503"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NGIxMTJjYTU3YjQyMDU5YjYwYTlhOWY0ZmY4YTA0L3NlYzo0NDRiMTEyY2E1N2I0MjA1OWI2MGE5YTlmNGZmOGEwNF8xL2ZyYWc6ZTkxNDZhZGU1OWMwNDNmZThhYjIzZTEyNzQ4YjI2MjYvdGFibGU6MjU1NzJmMzBlNzYzNGFkNDllMjc5YzM5NTJjYzg3NjEvdGFibGVyYW5nZToyNTU3MmYzMGU3NjM0YWQ0OWUyNzljMzk1MmNjODc2MV8xLTAtMS0xLTEwMTQxNw_c1b4df64-ff3b-40ba-8dfc-b4c544ee8630">Class A Common Stock of Evolent Health, Inc., par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="id598b4ef6927435d9f551b05ce16b3bb_D20230503-20230503"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NGIxMTJjYTU3YjQyMDU5YjYwYTlhOWY0ZmY4YTA0L3NlYzo0NDRiMTEyY2E1N2I0MjA1OWI2MGE5YTlmNGZmOGEwNF8xL2ZyYWc6ZTkxNDZhZGU1OWMwNDNmZThhYjIzZTEyNzQ4YjI2MjYvdGFibGU6MjU1NzJmMzBlNzYzNGFkNDllMjc5YzM5NTJjYzg3NjEvdGFibGVyYW5nZToyNTU3MmYzMGU3NjM0YWQ0OWUyNzljMzk1MmNjODc2MV8xLTEtMS0xLTEwMTQxNw_d1a37407-fd9e-4ed6-8b0f-7f434dc11afa">EVH</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="id598b4ef6927435d9f551b05ce16b3bb_D20230503-20230503"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NGIxMTJjYTU3YjQyMDU5YjYwYTlhOWY0ZmY4YTA0L3NlYzo0NDRiMTEyY2E1N2I0MjA1OWI2MGE5YTlmNGZmOGEwNF8xL2ZyYWc6ZTkxNDZhZGU1OWMwNDNmZThhYjIzZTEyNzQ4YjI2MjYvdGFibGU6MjU1NzJmMzBlNzYzNGFkNDllMjc5YzM5NTJjYzg3NjEvdGFibGVyYW5nZToyNTU3MmYzMGU3NjM0YWQ0OWUyNzljMzk1MmNjODc2MV8xLTItMS0xLTEwMTQxNw_1366a1c8-d4bc-4c70-90cc-acfaf71209d1">NYSE</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="id598b4ef6927435d9f551b05ce16b3bb_D20230503-20230503"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NGIxMTJjYTU3YjQyMDU5YjYwYTlhOWY0ZmY4YTA0L3NlYzo0NDRiMTEyY2E1N2I0MjA1OWI2MGE5YTlmNGZmOGEwNF8xL2ZyYWc6ZTkxNDZhZGU1OWMwNDNmZThhYjIzZTEyNzQ4YjI2MjYvdGV4dHJlZ2lvbjplOTE0NmFkZTU5YzA0M2ZlOGFiMjNlMTI3NDhiMjYyNl8xNjYw_06825aa7-8aa1-4d7c-9c3d-f287c95b7de7">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
M6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$
MT4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7<K_WUE[O)I#-ZG7TZSFN4
M?VFK :?MNYO/D_QSZ.2?IY/734+.<+PL"?'[(UMAAR=N.Q-R.AQG0GS/]O:1
MI24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG LR+7E$8D19_(
M+;KD$3BU20TR$S\(G8:8:E < J0),9:AAOBTQJP1X!-]M[X(R-^-B/>K;YH]
M5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M
MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZ<TT#PE"\D^DJ1CVFS(Z=T)LWH
M,QK!1J\;=8=HTCQZ_@7YG#4*')$;'0)G&[-&(81IN_ >KR2.FJW"$2M"/F(9
M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+
MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T
M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M>P#N+Y6R'R=N-U[\F3+\%U!+ P04    " #L@:-6GZ ;\+$"  #B#   #0
M 'AL+W-T>6QE<RYX;6S=5VUKVS 0_BM"/V!N8FKBD1BV0&&PC4+S85^56'8$
M>O%DN7/ZZZ>S;"=I=67=A['-H<G=/;J[1W<GF:Y;=Y+\X<BY([V2NMW0HW/-
M^R1I#T>N6/O.-%Q[I#)6,>=56R=M8SDK6W!2,EG>W&2)8D+38JT[=:=<2PZF
MTVY#;VA2K"NCSY:4!H-?RA0GCTQNZ)9)L;=B6,N4D*=@7H+A8*2QQ'DJ?$,7
M8&F? KP(&K <XRBAC05C$C*$[_VX_!DP::U7A90SP24-AF+=,.>XU7=>&18/
MQA<0&>7=J?$,:\M.B^4M/3L,/S[)WMB2VSG-@DZF8BUY!72LJ(_PZTR3 .B<
M45XH!:N-9@.'R6,4?-@#E_(!6OBMNHK=5R3TXE,);2"PU4GTA$8QA D*Q+^,
M%F)?A+W]K;"D$8_&?>S\;O2@?^^,X_>65Z(?]+Z:\V/1%WATUC3R]$&*6BL>
M]O[+"8LUF_S(T5CQY+/!I!R\@5M*'KEUXG!I^6%9L^.]FZ:IKW#.RW^0\Y^M
M<\TUMTQ>DO:C_S=7^2V,D_'T7!S1JP,Z6PE<A!OZ%>Y7>>9 ]IV03NA1.XJR
MY/K%.?7A'=O["_PJOE]?\HIUTNUF<$//\A=>BD[E\ZI[J,NXZBQ_AOMHD<VW
ML,\E=,E[7FY'U=;[021>\%G'!QR>(W?#$T<PGX#%$<"P/!@#S"=X87G^I_VL
MT/T$#..VBB(KU&>%^@2O&+(=/EB>N$_NG_A.\SQ-LPRKZ'8;9;#%ZI9E\!>/
MAG$##RP/9'I;K?%NXQ/R^AQ@/7UM0K"=XI.([12O-2#QNH%'GL>[C>4!#ZP+
MV.Q _G@>F*FX3YI"5S%NV G&D3S'$)C%^(QF&5*=##[Q_F"G)$WS/(X %F>0
MIA@"IQ%', ;  4/2='@//GL?)=-[*CG_5U/\!%!+ P04    " #L@:-6EXJ[
M',     3 @  "P   %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S9?$6
M!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X 4BV
M)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA<UYVE/=LO3T%O
M@*\Z3'%":4A+,P[PS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A(E@6FD7)TZ(=
MI7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0    (
M .R!HU;E:(KL.0$  #("   /    >&PO=V]R:V)O;VLN>&ULC5'1;L(P#/R5
M*A^PEFE#&J*\@+8A31L:$^^A=:E%$E>."QM?/[=5!=)>]F3[;%WN+O,S\7%/
M=$R^O0LQ-[5(,TO36-3@;;RC!H)N*F)O14<^I+%AL&6L <2[]#[+IJFW&,QB
M/G)M.+T=2* 0I*!@!^P0SO&Z[\;DA!'WZ%!^<M/W#DSB,:#'"Y2YR4P2:SJ_
M$N.%@EBW+9B<R\UD6.R !8L_\+83^67WL4?$[C^M"LG--%/""CE*?]'S6]5X
M CT>IE;H&9T KZS "U/;8#AT-.HBO;'1YS#6(<09_R=&JBHL8$5%ZR'(D".#
MZP2&6&,331*LA]PLZ02<;.P!DFO;^=,'U^7@553D37(\0UWPNASDCAI+J#!
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MJ#(9BBJ6<%H@XLD@;6E6?;!/3K3G>1<W]T6NS>,)KM\,<'AT_@%02P,$%
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M?^:+X3]>?P%02P$"% ,4    " #L@:-6!T%-8H$   "Q    $
M    @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( .R!HU;?EIO[
M[P   "L"   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+
M 0(4 Q0    ( .R!HU:97)PC$ 8  )PG   3              "  <T!  !X
M;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ [(&C5@64@19T!   6!$
M !@              ("!#@@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+
M 0(4 Q0    ( .R!HU:?H!OPL0(  .(,   -              "  ;@,  !X
M;"]S='EL97,N>&UL4$L! A0#%     @ [(&C5I>*NQS     $P(   L
M         ( !E \  %]R96QS+RYR96QS4$L! A0#%     @ [(&C5N5HBNPY
M 0  ,@(   \              ( !?1   'AL+W=O<FMB;V]K+GAM;%!+ 0(4
M Q0    ( .R!HU8D'INBK0   /@!   :              "  >,1  !X;"]?
M<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( .R!HU9ED'F2&0$
M ,\#   3              "  <@2  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%
3!@     )  D /@(  !(4      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="evh-20230503.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/CoverPageCoverPage</Role>
      <ShortName>Cover Page Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="evh-20230503.htm">evh-20230503.htm</File>
    <File>a1q23exhibit991.htm</File>
    <File>evh-20230503.xsd</File>
    <File>evh-20230503_def.xml</File>
    <File>evh-20230503_lab.xml</File>
    <File>evh-20230503_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "evh-20230503.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 23
   },
   "contextCount": 1,
   "dts": {
    "definitionLink": {
     "local": [
      "evh-20230503_def.xml"
     ]
    },
    "inline": {
     "local": [
      "evh-20230503.htm"
     ]
    },
    "labelLink": {
     "local": [
      "evh-20230503_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "evh-20230503_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "evh-20230503.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    }
   },
   "elementCount": 28,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2023": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "evh",
   "nsuri": "http://www.evolenthealth.com/20230503",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20230503.htm",
      "contextRef": "id598b4ef6927435d9f551b05ce16b3bb_D20230503-20230503",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:Security12bTitle",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover Page Cover Page",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.evolenthealth.com/role/CoverPageCoverPage",
     "shortName": "Cover Page Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20230503.htm",
      "contextRef": "id598b4ef6927435d9f551b05ce16b3bb_D20230503-20230503",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:Security12bTitle",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of the document as assigned by the filer, corresponding to SEC document naming convention standards.",
        "label": "Document [Domain]",
        "terseLabel": "Document [Domain]"
       }
      }
     },
     "localname": "DocumentDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_DocumentInformationDocumentAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.",
        "label": "Document Information, Document [Axis]",
        "terseLabel": "Document Information, Document [Axis]"
       }
      }
     },
     "localname": "DocumentInformationDocumentAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Document Information [Line Items]",
        "terseLabel": "Document Information [Line Items]"
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.",
        "label": "Document Information [Table]",
        "terseLabel": "Document Information [Table]"
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001628908-23-000061-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628908-23-000061-xbrl.zip
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MT2#/>R1<5G@%UH6X1C<T>L(G 27(IR<;>)3D!_?R.& EESPKC2L%P$IN?@W
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M>;.L>[L=R(P3F49NS_O1VSQT7-4T/NLU+'-RTD[U^$ZJ8,MRJ3*%^.;N$\R
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MXMK/5?V5A]EV)4\.KAJ]IM'K-<K<#:B2@#';1J==O,BA2]3MUK.,@>MSWSX
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M["EX@; M;:)FK8 &T<F6O\WYA.9]FO=IWJ=Y7[5YWT$.V,Y?)W;+F/3O$VP
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MH6OL[>;-=OW[P -<#=WHFQPM 8PB,4G2)N/?-D^H)&F<Y'',@T]XB#&(3/=
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MUQY%V_Y2#+E7/:@>5E&]UP_C,4\D!][4G:@95]\M(<3V$N'*#]BRMZ8/;;I
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M=&5=9F7E'%XYR3YPG'S/MF37!5/,5K& (4@NQ>T7I?GA27%F-#=>9Z6?-BT
MN7D"!2."Y'DKI![(OLP@R]7(]YU?7Q(L$Z.E0F&%0Y<.^N6L_;@O6%NTZ.9
M!I&?T-+?X<7YUD.09RX.2@LL*57A@^;,ZH+)Z(F!?AXGTY@'8$(/B2.:01]4
M3RC?$9YV@SX"=0:($!KHIC:;REE,0%D7R9X+B$5N91WW06?T*!M/$P3&Y*!6
MX.\AC\3BO@NAGAIJR[L,4N$FEYVJ/YG]>;YD#Y!5F+5(6+=IES_)[93<%0!$
MID#=;,AY=),T H,S^8'I;8.<95.AJ>FTZ.9^7GS-"E/DDQ;Y&JY\Y2C?"P"R
M >7O@<8K=(58Q>WK9FY/MBY["0"%;,-T>6?15>S5R,^3(UL"=A$ Y&9CG&_
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M"Q_LNU4WA:$]@VG9SVKHWH!J[G.3:+,<+2NFO5B_.;/OIMK$TW74>_RJ?['
MIH)HH00G0"IH8Q>%!# >1  KWP8OSA%6X31_?*BG)@%_?%WW7W9RH(>S#K[E
M#1K-S"*]S=13=)O/ZD*6C59%?&.31,S-XD:L;K PBT1@B?SM8_!?HO0L3*_
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MN^UWKWC[:&SP6+OM1EV<W6GC7H2Z2*(TFY=J_Q GYB(W\\54^8'OAS"PF7&
M *'82C7 !E _B)C@6G)JNI:DZCH:FVP?:S,;8+UO!5ROQ.M0L*KEMWWYJB]K
M0Q6S.A/F5-S:QT:O4E>MX<$+7_O<JRN#[6W??4@H3KG,/E^GB?EX.Y<FFQH2
M&2,T Q$D/B!0&< 5P4!"'"(:!HQAU'88V#8^-NF7^+P2H+=$V%[K.\0=UG<?
M.DZLZ0Y,=!)QD\M.PMTQ-IA8F]S8%&ACF^ZBO,Q$<;SOZ\-<IK-IB -MPD@
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M8NW-.;S=6Y>K\^7W8XL&\ML]N%R0;I"IHJ+KP5^?N,C\/[TZ;V"-EGL5CO'
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MW[WZ-U!+ 0(4 Q0    ( .R!HU;X4A:_C4L  'K_ P 3              "
M 0    !A,7$R,V5X:&EB:70Y.3$N:'1M4$L! A0#%     @ [(&C5O3R075_
M&0  -*<  !               ( !ODL  &5V:"TR,#(S,#4P,RYH=&U02P$"
M% ,4    " #L@:-65,TI"( "  "A"   $               @ %K90  979H
M+3(P,C,P-3 S+GAS9%!+ 0(4 Q0    ( .R!HU:"%NJ@%@@  *XZ   4
M          "  1EH  !E=F@M,C R,S U,#-?9&5F+GAM;%!+ 0(4 Q0    (
M .R!HU:GK\ S)PP  /1Q   4              "  6%P  !E=F@M,C R,S U
M,#-?;&%B+GAM;%!+ 0(4 Q0    ( .R!HU:IDU]EH@<   (]   4
M      "  ;I\  !E=F@M,C R,S U,#-?<')E+GAM;%!+!08     !@ & (,!
(  ".A      !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
